arie belldegrun  wikipedia arie belldegrun from wikipedia the free encyclopedia jump to navigation search arie s belldegrun born  age – israel residence los angeles california citizenship israeli and american alma mater hadassah medical center weizmann institute of science occupation chairman president and ceo of kite pharma years active present net worth us billion  spouses rebecka belldegrun children  relatives poju zabludowicz brotherinlaw arie s belldegrun born  is an israeliborn american urologic oncologist businessman and investor contents  early life and academia  career ventures  agensys  cougar biotechnology  two river  kite pharma  other board memberships  recent business  personal life  references  external links early life and academiaedit belldegrun was born in israel he received his medical degree from the hadassah medical center at hebrew university of jerusalem in  and conducted his postgraduate studies at the weizmann institute of science in  he completed his urologic surgery residency at harvard medical school in  and his surgical oncology fellowship at the national cancer institute in  he is certified by the american board of urology and is a fellow of the american college of surgeons and the american association of genitourinary surgeons belldegrun is the director of the ucla institute of urologic oncology professor of urology and chief of the division of urologic oncology at the david geffen school of medicine career venturesedit agensysedit in  belldegrun established agensys an earlystage privately held biotechnology company based in los angeles that is focused on the development of fully human monoclonal antibodies to treat solid tumor cancers in a variety of cancer targets he served as its founding chairman of the board of directors from  to  and then as a director until december  when agensys was acquired by astellas pharma in a deal valued at  million cougar biotechnologyedit belldegrun has been a founding vice chairman of the board of directors and chairman of the scientific advisory board of cougar biotechnology since  a los angelesbased company with a focus in the field of oncology in july  the company was acquired by johnson  johnson in a  million transaction in april  the united states food and drug administration approved abiraterone acetate zytiga cougar’s lead product for late stage prostate cancer two riveredit since  belldegrun has been the chairman and partner of two river a new yorkbased venture capital firm and merchant bank focused on the life science sector it specializes in investments in life science biotechnology and in firms focused on developing preventative and therapeutic technologies for a broad spectrum of disease areas including oncology cardiovascular disease neurological disorders and companion animal health care kite pharmaedit belldegrun is the chairman president and ceo of kite pharma nasdaq kite which he founded in  kite pharma is a clinicalstage biopharmaceutical company engaged in the development of novel cancer immunotherapy products with a primary focus on engineered autologous t cell therapy eact™ designed to restore the immune systems ability to recognize and eradicate tumors the company went public in june  belldegrun who owns  million shares of the company has a stake worth over  million today other board membershipsedit belldegrun also serves as a member of the following boards arno therapeutics otcbb arni  chairman since march  urogen pharma formerly theracoat  chairman since october  cell design labs  director oncura  chairman of the medical advisory board roei medical technologies  chairman of the medical advisory board pontifax  chairman lsm at the university of pennsylvania  member of the advisory board in the past belldegrun served as a member of a number of boards including teva nyse teva  director and vice chairman of the science  technology committee february  to january  sonacare medical formerly ushifu  director and urological advisor september  to  capricor therapeutics formerly nile therapeutics  director september  to november  talon therapeutics formerly hana biosciences  director chairman of the compensation committee and member of the nominating  governance committee april  to december  paramount acquisition  director june  to january  chem rx corporation  director june  to january  rencarex at wilex ag  chairman of the medical advisory board email real estatecom  director recent businessedit in may  theracoat a clinical stage specialty pharmaceutical company of which belldegrun is the chairman has raised  million in capital from private investors and venture funds also in may  kite pharma completed a  million financing of series a preferred stock in october  arno therapeutics completed a  million financing of equity in november  nile therapeutics completed a merger with capricor to form capricor therapeutics otcbb capr capricor has become a wholly owned subsidiary of nile in february  velcera a portfolio company of two river was acquired by perrigo for  million in june  kite pharma sold  shares in their ipo at  per share for net proceeds of  million the company listed on the nasdaq global market under the symbol “kite” in may  it was announced that theracoat is seeking to raise more than  million in the coming months as it prepares for an initial public offering in new york the company will seek a valuation of about  million in the ipo in january  arno therapeutics completed a  million financing of equity in august  arno therapeutics completed a  million private placement of its common stock in april  urogen pharma formerly theracoat filed with the us securities and exchange commission sec to raise up to  million in an ipo on nasdaq the companys value has not yet been disclosed the company plans to list on the nasdaq under the symbol urgn jefferies and cowen  company are the joint bookrunners on the deal personal lifeedit belldegrun is married to dr rebecka belldegrun and together they have four children they reside in bel air an affluent neighborhood in los angeles their oldest son ben belldegrun a hedge fund manager is married to kelly bergantz senior producer for syco in  according to the bloomberg pay index belldegrun was ranked the th highestpaid executive in the united states with a pay package valued at  million in  the hollywood reporters annual hollywoods top doctors list included belldegrun as one of the highestrated urologists in  in its annual ranking of the wealthiest people in israel forbes israel ranked arie and rebecka belldegrun th with a personal net worth of ₪ billion equal to us billion belldegrun has written over  scientific publications related to urologic oncology and has authored several books on prostate and kidney cancers he was one of the speakers at the milken institute global conference  delivered the keynote andrew c novick memorial lecture at the ninth international kidney cancer symposium and regularly presents at the annual jp morgan healthcare conference it was announced that belldegrun will present at the th annual jp morgan healthcare conference in january  arie and rebecka belldegrun have donated over  million to the university of pennsylvania school of arts and sciences and have donated a  million sculpture to lacma referencesedit  a b  העשירים בישראל  in hebrew forbes israel  september  retrieved  september   a b curriculum vitae infofaq july  retrieved on  june   dr arie s belldegrun md facs joins two river group holdings as chairman and partner reuters  april  retrieved  june   arie belldegrun md archived july   at the wayback machine ucla health retrieved on  june   arie belldegrun md david geffen school of medicine retrieved on  june   a b arie belldegrun md usrf retrieved on  june   advisory board penn lsm retrieved on  august   moster roxanne  champeau rachel  november  ucla scientists biotech firm to be acquired by pharmaceutical corp ucla newsroom retrieved  june   board of directors archived june   at the wayback machine nile therapeutics retrieved on  june   johnson  johnson completes acquisition of cougar biotechnology archived november   at the wayback machine cougar biotechnology  july  retrieved  june   board of directors arno therapeutics retrieved on  june   company overview of two river group holdings llc businessweek retrieved on  june   about kite pharma archived january   at the wayback machine kite pharma retrieved  january   morrell alex  december  who got rich this week ucla doctor with a cancerfighting pharma firm forbes retrieved  march   a b arie s belldegrun md facs bloomberg business  august  retrieved on  august   advisory board university of pennsylvania retrieved  june   teva’s arie belldegrun resigns the pharma letter  january  retrieved  february   theracoat has completed a capital raising of m led by pontifax and chaim hurvitzs chealth fund the wall street journal  may  retrieved  june   elliott peter  may  kite pharma completes  million series a preferred stock financing archived april   at the wayback machine istreetwire retrieved  june   arno therapeutics completes  million financing recapitalization and for reverse stock split  the wall street journal new york  october  retrieved  october   capricor and nile therapeutics complete merger to form capricor therapeutics inc  bloomberg  november  retrieved  december   ail pallavi  february  perrigo expands further into pet care with velcera deal reuters retrieved  april   “kite pharma announces pricing of initial public offering” kite pharma  june  retrieved  august   calia michael  june  kite pharma soars above ipo price on first day of trading the wall street journal retrieved  june   “kite pharma announces full exercise of underwriters option to purchase additional shares” kite pharma  june  retrieved  august   wainer david  may  israel’s theracoat said to seek more than  million before ipo bloomberg retrieved  december   arno therapeutics completes  million common stock financing nasdaq  january  retrieved  january   arno completes  million private placement digital journal  august  retrieved  august   weinreb gali  tsipori tali  april  urogen pharma files for m nasdaq ipo globes retrieved  april   architecture project entries  aiany  retrieved on  june   kay richard  october  richard kay cowell girl gets the yes factor daily mail london retrieved  may   melin anders  chen caroline  june  biotech ceos among highestpaid us execs telegramcom retrieved  july   pyun jeanie  august   the hollywood reporter retrieved  november   nile therapeutics appoints arie s belldegrun md to board of directors reuters retrieved  november   us hifu appoints arie belldegrun md to board of directors reuters retrieved  november   global conference  archived november   at the wayback machine milken institute retrieved  november   medical symposia keynote addresses archived november   at the wayback machine kidney cancer association retrieved  november   kite pharma to present at the nd annual jp morgan healthcare conference bizjournals charlotte  january  retrieved  may   kite pharma to present at the th annual jp morgan healthcare conference nasdaq  january  retrieved  january   m lifetime donors to the school of arts and sciences university of pennsylvania  june  retrieved  june   smoke  lacma collections lacma retrieved  june   tony smiths monumental sculpture smoke will not disappear from lacma multimilliondollar purchase finalized los angeles times  june  retrieved  june  external linksedit arie belldegrun on bloomberg retrieved from httpsenwikipediaorgwindexphptitleariebelldegrunoldid categories  birthsliving peopleamerican bankersamerican chairmen of corporationsamerican health care businesspeopleamerican investorsamerican medical academicsamerican oncologistsamerican technology chief executivesamerican technology company foundersamerican urologistsamerican venture capitalistsbusinesspeople from los angelesbusinesspeople in the pharmaceutical industryhebrew university of jerusalem alumniisraeli emigrants to the united statesisraeli jewsjewish american bankersjewish physicianspeople from bel air los angelesphysicians from californiaweizmann institute of science alumnihidden categories webarchive template wayback linksarticles with hcards navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  june  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view arie belldegrun  wikipedia arie belldegrun from wikipedia the free encyclopedia jump to navigation search arie s belldegrun born  age – israel residence los angeles california citizenship israeli and american alma mater hadassah medical center weizmann institute of science occupation chairman president and ceo of kite pharma years active present net worth us billion  spouses rebecka belldegrun children  relatives poju zabludowicz brotherinlaw arie s belldegrun born  is an israeliborn american urologic oncologist businessman and investor contents  early life and academia  career ventures  agensys  cougar biotechnology  two river  kite pharma  other board memberships  recent business  personal life  references  external links early life and academiaedit belldegrun was born in israel he received his medical degree from the hadassah medical center at hebrew university of jerusalem in  and conducted his postgraduate studies at the weizmann institute of science in  he completed his urologic surgery residency at harvard medical school in  and his surgical oncology fellowship at the national cancer institute in  he is certified by the american board of urology and is a fellow of the american college of surgeons and the american association of genitourinary surgeons belldegrun is the director of the ucla institute of urologic oncology professor of urology and chief of the division of urologic oncology at the david geffen school of medicine career venturesedit agensysedit in  belldegrun established agensys an earlystage privately held biotechnology company based in los angeles that is focused on the development of fully human monoclonal antibodies to treat solid tumor cancers in a variety of cancer targets he served as its founding chairman of the board of directors from  to  and then as a director until december  when agensys was acquired by astellas pharma in a deal valued at  million cougar biotechnologyedit belldegrun has been a founding vice chairman of the board of directors and chairman of the scientific advisory board of cougar biotechnology since  a los angelesbased company with a focus in the field of oncology in july  the company was acquired by johnson  johnson in a  million transaction in april  the united states food and drug administration approved abiraterone acetate zytiga cougar’s lead product for late stage prostate cancer two riveredit since  belldegrun has been the chairman and partner of two river a new yorkbased venture capital firm and merchant bank focused on the life science sector it specializes in investments in life science biotechnology and in firms focused on developing preventative and therapeutic technologies for a broad spectrum of disease areas including oncology cardiovascular disease neurological disorders and companion animal health care kite pharmaedit belldegrun is the chairman president and ceo of kite pharma nasdaq kite which he founded in  kite pharma is a clinicalstage biopharmaceutical company engaged in the development of novel cancer immunotherapy products with a primary focus on engineered autologous t cell therapy eact™ designed to restore the immune systems ability to recognize and eradicate tumors the company went public in june  belldegrun who owns  million shares of the company has a stake worth over  million today other board membershipsedit belldegrun also serves as a member of the following boards arno therapeutics otcbb arni  chairman since march  urogen pharma formerly theracoat  chairman since october  cell design labs  director oncura  chairman of the medical advisory board roei medical technologies  chairman of the medical advisory board pontifax  chairman lsm at the university of pennsylvania  member of the advisory board in the past belldegrun served as a member of a number of boards including teva nyse teva  director and vice chairman of the science  technology committee february  to january  sonacare medical formerly ushifu  director and urological advisor september  to  capricor therapeutics formerly nile therapeutics  director september  to november  talon therapeutics formerly hana biosciences  director chairman of the compensation committee and member of the nominating  governance committee april  to december  paramount acquisition  director june  to january  chem rx corporation  director june  to january  rencarex at wilex ag  chairman of the medical advisory board email real estatecom  director recent businessedit in may  theracoat a clinical stage specialty pharmaceutical company of which belldegrun is the chairman has raised  million in capital from private investors and venture funds also in may  kite pharma completed a  million financing of series a preferred stock in october  arno therapeutics completed a  million financing of equity in november  nile therapeutics completed a merger with capricor to form capricor therapeutics otcbb capr capricor has become a wholly owned subsidiary of nile in february  velcera a portfolio company of two river was acquired by perrigo for  million in june  kite pharma sold  shares in their ipo at  per share for net proceeds of  million the company listed on the nasdaq global market under the symbol “kite” in may  it was announced that theracoat is seeking to raise more than  million in the coming months as it prepares for an initial public offering in new york the company will seek a valuation of about  million in the ipo in january  arno therapeutics completed a  million financing of equity in august  arno therapeutics completed a  million private placement of its common stock in april  urogen pharma formerly theracoat filed with the us securities and exchange commission sec to raise up to  million in an ipo on nasdaq the companys value has not yet been disclosed the company plans to list on the nasdaq under the symbol urgn jefferies and cowen  company are the joint bookrunners on the deal personal lifeedit belldegrun is married to dr rebecka belldegrun and together they have four children they reside in bel air an affluent neighborhood in los angeles their oldest son ben belldegrun a hedge fund manager is married to kelly bergantz senior producer for syco in  according to the bloomberg pay index belldegrun was ranked the th highestpaid executive in the united states with a pay package valued at  million in  the hollywood reporters annual hollywoods top doctors list included belldegrun as one of the highestrated urologists in  in its annual ranking of the wealthiest people in israel forbes israel ranked arie and rebecka belldegrun th with a personal net worth of ₪ billion equal to us billion belldegrun has written over  scientific publications related to urologic oncology and has authored several books on prostate and kidney cancers he was one of the speakers at the milken institute global conference  delivered the keynote andrew c novick memorial lecture at the ninth international kidney cancer symposium and regularly presents at the annual jp morgan healthcare conference it was announced that belldegrun will present at the th annual jp morgan healthcare conference in january  arie and rebecka belldegrun have donated over  million to the university of pennsylvania school of arts and sciences and have donated a  million sculpture to lacma referencesedit  a b  העשירים בישראל  in hebrew forbes israel  september  retrieved  september   a b curriculum vitae infofaq july  retrieved on  june   dr arie s belldegrun md facs joins two river group holdings as chairman and partner reuters  april  retrieved  june   arie belldegrun md archived july   at the wayback machine ucla health retrieved on  june   arie belldegrun md david geffen school of medicine retrieved on  june   a b arie belldegrun md usrf retrieved on  june   advisory board penn lsm retrieved on  august   moster roxanne  champeau rachel  november  ucla scientists biotech firm to be acquired by pharmaceutical corp ucla newsroom retrieved  june   board of directors archived june   at the wayback machine nile therapeutics retrieved on  june   johnson  johnson completes acquisition of cougar biotechnology archived november   at the wayback machine cougar biotechnology  july  retrieved  june   board of directors arno therapeutics retrieved on  june   company overview of two river group holdings llc businessweek retrieved on  june   about kite pharma archived january   at the wayback machine kite pharma retrieved  january   morrell alex  december  who got rich this week ucla doctor with a cancerfighting pharma firm forbes retrieved  march   a b arie s belldegrun md facs bloomberg business  august  retrieved on  august   advisory board university of pennsylvania retrieved  june   teva’s arie belldegrun resigns the pharma letter  january  retrieved  february   theracoat has completed a capital raising of m led by pontifax and chaim hurvitzs chealth fund the wall street journal  may  retrieved  june   elliott peter  may  kite pharma completes  million series a preferred stock financing archived april   at the wayback machine istreetwire retrieved  june   arno therapeutics completes  million financing recapitalization and for reverse stock split  the wall street journal new york  october  retrieved  october   capricor and nile therapeutics complete merger to form capricor therapeutics inc  bloomberg  november  retrieved  december   ail pallavi  february  perrigo expands further into pet care with velcera deal reuters retrieved  april   “kite pharma announces pricing of initial public offering” kite pharma  june  retrieved  august   calia michael  june  kite pharma soars above ipo price on first day of trading the wall street journal retrieved  june   “kite pharma announces full exercise of underwriters option to purchase additional shares” kite pharma  june  retrieved  august   wainer david  may  israel’s theracoat said to seek more than  million before ipo bloomberg retrieved  december   arno therapeutics completes  million common stock financing nasdaq  january  retrieved  january   arno completes  million private placement digital journal  august  retrieved  august   weinreb gali  tsipori tali  april  urogen pharma files for m nasdaq ipo globes retrieved  april   architecture project entries  aiany  retrieved on  june   kay richard  october  richard kay cowell girl gets the yes factor daily mail london retrieved  may   melin anders  chen caroline  june  biotech ceos among highestpaid us execs telegramcom retrieved  july   pyun jeanie  august   the hollywood reporter retrieved  november   nile therapeutics appoints arie s belldegrun md to board of directors reuters retrieved  november   us hifu appoints arie belldegrun md to board of directors reuters retrieved  november   global conference  archived november   at the wayback machine milken institute retrieved  november   medical symposia keynote addresses archived november   at the wayback machine kidney cancer association retrieved  november   kite pharma to present at the nd annual jp morgan healthcare conference bizjournals charlotte  january  retrieved  may   kite pharma to present at the th annual jp morgan healthcare conference nasdaq  january  retrieved  january   m lifetime donors to the school of arts and sciences university of pennsylvania  june  retrieved  june   smoke  lacma collections lacma retrieved  june   tony smiths monumental sculpture smoke will not disappear from lacma multimilliondollar purchase finalized los angeles times  june  retrieved  june  external linksedit arie belldegrun on bloomberg retrieved from httpsenwikipediaorgwindexphptitleariebelldegrunoldid categories  birthsliving peopleamerican bankersamerican chairmen of corporationsamerican health care businesspeopleamerican investorsamerican medical academicsamerican oncologistsamerican technology chief executivesamerican technology company foundersamerican urologistsamerican venture capitalistsbusinesspeople from los angelesbusinesspeople in the pharmaceutical industryhebrew university of jerusalem alumniisraeli emigrants to the united statesisraeli jewsjewish american bankersjewish physicianspeople from bel air los angelesphysicians from californiaweizmann institute of science alumnihidden categories webarchive template wayback linksarticles with hcards navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  june  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view arie belldegrun  wikipedia arie belldegrun from wikipedia the free encyclopedia jump to navigation search arie s belldegrun born  age – israel residence los angeles california citizenship israeli and american alma mater hadassah medical center weizmann institute of science occupation chairman president and ceo of kite pharma years active present net worth us billion  spouses rebecka belldegrun children  relatives poju zabludowicz brotherinlaw arie s belldegrun born  is an israeliborn american urologic oncologist businessman and investor contents  early life and academia  career ventures  agensys  cougar biotechnology  two river  kite pharma  other board memberships  recent business  personal life  references  external links early life and academiaedit belldegrun was born in israel he received his medical degree from the hadassah medical center at hebrew university of jerusalem in  and conducted his postgraduate studies at the weizmann institute of science in  he completed his urologic surgery residency at harvard medical school in  and his surgical oncology fellowship at the national cancer institute in  he is certified by the american board of urology and is a fellow of the american college of surgeons and the american association of genitourinary surgeons belldegrun is the director of the ucla institute of urologic oncology professor of urology and chief of the division of urologic oncology at the david geffen school of medicine career venturesedit agensysedit in  belldegrun established agensys an earlystage privately held biotechnology company based in los angeles that is focused on the development of fully human monoclonal antibodies to treat solid tumor cancers in a variety of cancer targets he served as its founding chairman of the board of directors from  to  and then as a director until december  when agensys was acquired by astellas pharma in a deal valued at  million cougar biotechnologyedit belldegrun has been a founding vice chairman of the board of directors and chairman of the scientific advisory board of cougar biotechnology since  a los angelesbased company with a focus in the field of oncology in july  the company was acquired by johnson  johnson in a  million transaction in april  the united states food and drug administration approved abiraterone acetate zytiga cougar’s lead product for late stage prostate cancer two riveredit since  belldegrun has been the chairman and partner of two river a new yorkbased venture capital firm and merchant bank focused on the life science sector it specializes in investments in life science biotechnology and in firms focused on developing preventative and therapeutic technologies for a broad spectrum of disease areas including oncology cardiovascular disease neurological disorders and companion animal health care kite pharmaedit belldegrun is the chairman president and ceo of kite pharma nasdaq kite which he founded in  kite pharma is a clinicalstage biopharmaceutical company engaged in the development of novel cancer immunotherapy products with a primary focus on engineered autologous t cell therapy eact™ designed to restore the immune systems ability to recognize and eradicate tumors the company went public in june  belldegrun who owns  million shares of the company has a stake worth over  million today other board membershipsedit belldegrun also serves as a member of the following boards arno therapeutics otcbb arni  chairman since march  urogen pharma formerly theracoat  chairman since october  cell design labs  director oncura  chairman of the medical advisory board roei medical technologies  chairman of the medical advisory board pontifax  chairman lsm at the university of pennsylvania  member of the advisory board in the past belldegrun served as a member of a number of boards including teva nyse teva  director and vice chairman of the science  technology committee february  to january  sonacare medical formerly ushifu  director and urological advisor september  to  capricor therapeutics formerly nile therapeutics  director september  to november  talon therapeutics formerly hana biosciences  director chairman of the compensation committee and member of the nominating  governance committee april  to december  paramount acquisition  director june  to january  chem rx corporation  director june  to january  rencarex at wilex ag  chairman of the medical advisory board email real estatecom  director recent businessedit in may  theracoat a clinical stage specialty pharmaceutical company of which belldegrun is the chairman has raised  million in capital from private investors and venture funds also in may  kite pharma completed a  million financing of series a preferred stock in october  arno therapeutics completed a  million financing of equity in november  nile therapeutics completed a merger with capricor to form capricor therapeutics otcbb capr capricor has become a wholly owned subsidiary of nile in february  velcera a portfolio company of two river was acquired by perrigo for  million in june  kite pharma sold  shares in their ipo at  per share for net proceeds of  million the company listed on the nasdaq global market under the symbol “kite” in may  it was announced that theracoat is seeking to raise more than  million in the coming months as it prepares for an initial public offering in new york the company will seek a valuation of about  million in the ipo in january  arno therapeutics completed a  million financing of equity in august  arno therapeutics completed a  million private placement of its common stock in april  urogen pharma formerly theracoat filed with the us securities and exchange commission sec to raise up to  million in an ipo on nasdaq the companys value has not yet been disclosed the company plans to list on the nasdaq under the symbol urgn jefferies and cowen  company are the joint bookrunners on the deal personal lifeedit belldegrun is married to dr rebecka belldegrun and together they have four children they reside in bel air an affluent neighborhood in los angeles their oldest son ben belldegrun a hedge fund manager is married to kelly bergantz senior producer for syco in  according to the bloomberg pay index belldegrun was ranked the th highestpaid executive in the united states with a pay package valued at  million in  the hollywood reporters annual hollywoods top doctors list included belldegrun as one of the highestrated urologists in  in its annual ranking of the wealthiest people in israel forbes israel ranked arie and rebecka belldegrun th with a personal net worth of ₪ billion equal to us billion belldegrun has written over  scientific publications related to urologic oncology and has authored several books on prostate and kidney cancers he was one of the speakers at the milken institute global conference  delivered the keynote andrew c novick memorial lecture at the ninth international kidney cancer symposium and regularly presents at the annual jp morgan healthcare conference it was announced that belldegrun will present at the th annual jp morgan healthcare conference in january  arie and rebecka belldegrun have donated over  million to the university of pennsylvania school of arts and sciences and have donated a  million sculpture to lacma referencesedit  a b  העשירים בישראל  in hebrew forbes israel  september  retrieved  september   a b curriculum vitae infofaq july  retrieved on  june   dr arie s belldegrun md facs joins two river group holdings as chairman and partner reuters  april  retrieved  june   arie belldegrun md archived july   at the wayback machine ucla health retrieved on  june   arie belldegrun md david geffen school of medicine retrieved on  june   a b arie belldegrun md usrf retrieved on  june   advisory board penn lsm retrieved on  august   moster roxanne  champeau rachel  november  ucla scientists biotech firm to be acquired by pharmaceutical corp ucla newsroom retrieved  june   board of directors archived june   at the wayback machine nile therapeutics retrieved on  june   johnson  johnson completes acquisition of cougar biotechnology archived november   at the wayback machine cougar biotechnology  july  retrieved  june   board of directors arno therapeutics retrieved on  june   company overview of two river group holdings llc businessweek retrieved on  june   about kite pharma archived january   at the wayback machine kite pharma retrieved  january   morrell alex  december  who got rich this week ucla doctor with a cancerfighting pharma firm forbes retrieved  march   a b arie s belldegrun md facs bloomberg business  august  retrieved on  august   advisory board university of pennsylvania retrieved  june   teva’s arie belldegrun resigns the pharma letter  january  retrieved  february   theracoat has completed a capital raising of m led by pontifax and chaim hurvitzs chealth fund the wall street journal  may  retrieved  june   elliott peter  may  kite pharma completes  million series a preferred stock financing archived april   at the wayback machine istreetwire retrieved  june   arno therapeutics completes  million financing recapitalization and for reverse stock split  the wall street journal new york  october  retrieved  october   capricor and nile therapeutics complete merger to form capricor therapeutics inc  bloomberg  november  retrieved  december   ail pallavi  february  perrigo expands further into pet care with velcera deal reuters retrieved  april   “kite pharma announces pricing of initial public offering” kite pharma  june  retrieved  august   calia michael  june  kite pharma soars above ipo price on first day of trading the wall street journal retrieved  june   “kite pharma announces full exercise of underwriters option to purchase additional shares” kite pharma  june  retrieved  august   wainer david  may  israel’s theracoat said to seek more than  million before ipo bloomberg retrieved  december   arno therapeutics completes  million common stock financing nasdaq  january  retrieved  january   arno completes  million private placement digital journal  august  retrieved  august   weinreb gali  tsipori tali  april  urogen pharma files for m nasdaq ipo globes retrieved  april   architecture project entries  aiany  retrieved on  june   kay richard  october  richard kay cowell girl gets the yes factor daily mail london retrieved  may   melin anders  chen caroline  june  biotech ceos among highestpaid us execs telegramcom retrieved  july   pyun jeanie  august   the hollywood reporter retrieved  november   nile therapeutics appoints arie s belldegrun md to board of directors reuters retrieved  november   us hifu appoints arie belldegrun md to board of directors reuters retrieved  november   global conference  archived november   at the wayback machine milken institute retrieved  november   medical symposia keynote addresses archived november   at the wayback machine kidney cancer association retrieved  november   kite pharma to present at the nd annual jp morgan healthcare conference bizjournals charlotte  january  retrieved  may   kite pharma to present at the th annual jp morgan healthcare conference nasdaq  january  retrieved  january   m lifetime donors to the school of arts and sciences university of pennsylvania  june  retrieved  june   smoke  lacma collections lacma retrieved  june   tony smiths monumental sculpture smoke will not disappear from lacma multimilliondollar purchase finalized los angeles times  june  retrieved  june  external linksedit arie belldegrun on bloomberg retrieved from httpsenwikipediaorgwindexphptitleariebelldegrunoldid categories  birthsliving peopleamerican bankersamerican chairmen of corporationsamerican health care businesspeopleamerican investorsamerican medical academicsamerican oncologistsamerican technology chief executivesamerican technology company foundersamerican urologistsamerican venture capitalistsbusinesspeople from los angelesbusinesspeople in the pharmaceutical industryhebrew university of jerusalem alumniisraeli emigrants to the united statesisraeli jewsjewish american bankersjewish physicianspeople from bel air los angelesphysicians from californiaweizmann institute of science alumnihidden categories webarchive template wayback linksarticles with hcards navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  june  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view arie belldegrun  wikipedia arie belldegrun from wikipedia the free encyclopedia jump to navigation search arie s belldegrun born  age – israel residence los angeles california citizenship israeli and american alma mater hadassah medical center weizmann institute of science occupation chairman president and ceo of kite pharma years active present net worth us billion  spouses rebecka belldegrun children  relatives poju zabludowicz brotherinlaw arie s belldegrun born  is an israeliborn american urologic oncologist businessman and investor contents  early life and academia  career ventures  agensys  cougar biotechnology  two river  kite pharma  other board memberships  recent business  personal life  references  external links early life and academiaedit belldegrun was born in israel he received his medical degree from the hadassah medical center at hebrew university of jerusalem in  and conducted his postgraduate studies at the weizmann institute of science in  he completed his urologic surgery residency at harvard medical school in  and his surgical oncology fellowship at the national cancer institute in  he is certified by the american board of urology and is a fellow of the american college of surgeons and the american association of genitourinary surgeons belldegrun is the director of the ucla institute of urologic oncology professor of urology and chief of the division of urologic oncology at the david geffen school of medicine career venturesedit agensysedit in  belldegrun established agensys an earlystage privately held biotechnology company based in los angeles that is focused on the development of fully human monoclonal antibodies to treat solid tumor cancers in a variety of cancer targets he served as its founding chairman of the board of directors from  to  and then as a director until december  when agensys was acquired by astellas pharma in a deal valued at  million cougar biotechnologyedit belldegrun has been a founding vice chairman of the board of directors and chairman of the scientific advisory board of cougar biotechnology since  a los angelesbased company with a focus in the field of oncology in july  the company was acquired by johnson  johnson in a  million transaction in april  the united states food and drug administration approved abiraterone acetate zytiga cougar’s lead product for late stage prostate cancer two riveredit since  belldegrun has been the chairman and partner of two river a new yorkbased venture capital firm and merchant bank focused on the life science sector it specializes in investments in life science biotechnology and in firms focused on developing preventative and therapeutic technologies for a broad spectrum of disease areas including oncology cardiovascular disease neurological disorders and companion animal health care kite pharmaedit belldegrun is the chairman president and ceo of kite pharma nasdaq kite which he founded in  kite pharma is a clinicalstage biopharmaceutical company engaged in the development of novel cancer immunotherapy products with a primary focus on engineered autologous t cell therapy eact™ designed to restore the immune systems ability to recognize and eradicate tumors the company went public in june  belldegrun who owns  million shares of the company has a stake worth over  million today other board membershipsedit belldegrun also serves as a member of the following boards arno therapeutics otcbb arni  chairman since march  urogen pharma formerly theracoat  chairman since october  cell design labs  director oncura  chairman of the medical advisory board roei medical technologies  chairman of the medical advisory board pontifax  chairman lsm at the university of pennsylvania  member of the advisory board in the past belldegrun served as a member of a number of boards including teva nyse teva  director and vice chairman of the science  technology committee february  to january  sonacare medical formerly ushifu  director and urological advisor september  to  capricor therapeutics formerly nile therapeutics  director september  to november  talon therapeutics formerly hana biosciences  director chairman of the compensation committee and member of the nominating  governance committee april  to december  paramount acquisition  director june  to january  chem rx corporation  director june  to january  rencarex at wilex ag  chairman of the medical advisory board email real estatecom  director recent businessedit in may  theracoat a clinical stage specialty pharmaceutical company of which belldegrun is the chairman has raised  million in capital from private investors and venture funds also in may  kite pharma completed a  million financing of series a preferred stock in october  arno therapeutics completed a  million financing of equity in november  nile therapeutics completed a merger with capricor to form capricor therapeutics otcbb capr capricor has become a wholly owned subsidiary of nile in february  velcera a portfolio company of two river was acquired by perrigo for  million in june  kite pharma sold  shares in their ipo at  per share for net proceeds of  million the company listed on the nasdaq global market under the symbol “kite” in may  it was announced that theracoat is seeking to raise more than  million in the coming months as it prepares for an initial public offering in new york the company will seek a valuation of about  million in the ipo in january  arno therapeutics completed a  million financing of equity in august  arno therapeutics completed a  million private placement of its common stock in april  urogen pharma formerly theracoat filed with the us securities and exchange commission sec to raise up to  million in an ipo on nasdaq the companys value has not yet been disclosed the company plans to list on the nasdaq under the symbol urgn jefferies and cowen  company are the joint bookrunners on the deal personal lifeedit belldegrun is married to dr rebecka belldegrun and together they have four children they reside in bel air an affluent neighborhood in los angeles their oldest son ben belldegrun a hedge fund manager is married to kelly bergantz senior producer for syco in  according to the bloomberg pay index belldegrun was ranked the th highestpaid executive in the united states with a pay package valued at  million in  the hollywood reporters annual hollywoods top doctors list included belldegrun as one of the highestrated urologists in  in its annual ranking of the wealthiest people in israel forbes israel ranked arie and rebecka belldegrun th with a personal net worth of ₪ billion equal to us billion belldegrun has written over  scientific publications related to urologic oncology and has authored several books on prostate and kidney cancers he was one of the speakers at the milken institute global conference  delivered the keynote andrew c novick memorial lecture at the ninth international kidney cancer symposium and regularly presents at the annual jp morgan healthcare conference it was announced that belldegrun will present at the th annual jp morgan healthcare conference in january  arie and rebecka belldegrun have donated over  million to the university of pennsylvania school of arts and sciences and have donated a  million sculpture to lacma referencesedit  a b  העשירים בישראל  in hebrew forbes israel  september  retrieved  september   a b curriculum vitae infofaq july  retrieved on  june   dr arie s belldegrun md facs joins two river group holdings as chairman and partner reuters  april  retrieved  june   arie belldegrun md archived july   at the wayback machine ucla health retrieved on  june   arie belldegrun md david geffen school of medicine retrieved on  june   a b arie belldegrun md usrf retrieved on  june   advisory board penn lsm retrieved on  august   moster roxanne  champeau rachel  november  ucla scientists biotech firm to be acquired by pharmaceutical corp ucla newsroom retrieved  june   board of directors archived june   at the wayback machine nile therapeutics retrieved on  june   johnson  johnson completes acquisition of cougar biotechnology archived november   at the wayback machine cougar biotechnology  july  retrieved  june   board of directors arno therapeutics retrieved on  june   company overview of two river group holdings llc businessweek retrieved on  june   about kite pharma archived january   at the wayback machine kite pharma retrieved  january   morrell alex  december  who got rich this week ucla doctor with a cancerfighting pharma firm forbes retrieved  march   a b arie s belldegrun md facs bloomberg business  august  retrieved on  august   advisory board university of pennsylvania retrieved  june   teva’s arie belldegrun resigns the pharma letter  january  retrieved  february   theracoat has completed a capital raising of m led by pontifax and chaim hurvitzs chealth fund the wall street journal  may  retrieved  june   elliott peter  may  kite pharma completes  million series a preferred stock financing archived april   at the wayback machine istreetwire retrieved  june   arno therapeutics completes  million financing recapitalization and for reverse stock split  the wall street journal new york  october  retrieved  october   capricor and nile therapeutics complete merger to form capricor therapeutics inc  bloomberg  november  retrieved  december   ail pallavi  february  perrigo expands further into pet care with velcera deal reuters retrieved  april   “kite pharma announces pricing of initial public offering” kite pharma  june  retrieved  august   calia michael  june  kite pharma soars above ipo price on first day of trading the wall street journal retrieved  june   “kite pharma announces full exercise of underwriters option to purchase additional shares” kite pharma  june  retrieved  august   wainer david  may  israel’s theracoat said to seek more than  million before ipo bloomberg retrieved  december   arno therapeutics completes  million common stock financing nasdaq  january  retrieved  january   arno completes  million private placement digital journal  august  retrieved  august   weinreb gali  tsipori tali  april  urogen pharma files for m nasdaq ipo globes retrieved  april   architecture project entries  aiany  retrieved on  june   kay richard  october  richard kay cowell girl gets the yes factor daily mail london retrieved  may   melin anders  chen caroline  june  biotech ceos among highestpaid us execs telegramcom retrieved  july   pyun jeanie  august   the hollywood reporter retrieved  november   nile therapeutics appoints arie s belldegrun md to board of directors reuters retrieved  november   us hifu appoints arie belldegrun md to board of directors reuters retrieved  november   global conference  archived november   at the wayback machine milken institute retrieved  november   medical symposia keynote addresses archived november   at the wayback machine kidney cancer association retrieved  november   kite pharma to present at the nd annual jp morgan healthcare conference bizjournals charlotte  january  retrieved  may   kite pharma to present at the th annual jp morgan healthcare conference nasdaq  january  retrieved  january   m lifetime donors to the school of arts and sciences university of pennsylvania  june  retrieved  june   smoke  lacma collections lacma retrieved  june   tony smiths monumental sculpture smoke will not disappear from lacma multimilliondollar purchase finalized los angeles times  june  retrieved  june  external linksedit arie belldegrun on bloomberg retrieved from httpsenwikipediaorgwindexphptitleariebelldegrunoldid categories  birthsliving peopleamerican bankersamerican chairmen of corporationsamerican health care businesspeopleamerican investorsamerican medical academicsamerican oncologistsamerican technology chief executivesamerican technology company foundersamerican urologistsamerican venture capitalistsbusinesspeople from los angelesbusinesspeople in the pharmaceutical industryhebrew university of jerusalem alumniisraeli emigrants to the united statesisraeli jewsjewish american bankersjewish physicianspeople from bel air los angelesphysicians from californiaweizmann institute of science alumnihidden categories webarchive template wayback linksarticles with hcards navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  june  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view arie belldegrun md arie belldegrun md ucla school of medicine  le conte avenue chs  div of urology los angeles ca  phone   email abelldegrunmednetuclaedu slides modem  broadband arie belldegrun md arie belldegrun md is chief of the division of urologic oncology and director of urologic research in the department of urology at the university of california los angeles he is a ucla professor of urology clinical director of the ucla prostate disease research program and surgical director of the ucla kidney cancer program he is also the founder and chairman of the board of agensys inc a privately held biotechnology company focusing on the discovery and development of novel and innovative products for the diagnosis and treatment of urological diseases he has also been appointed as a member of the governors council on bioscience he completed his medical degree at the hebrew university hadassah medical school in jerusalem his post graduate fellowship at the weizmann institute of science and his residency in urology at harvard medical school prior to ucla dr belldegrun was at the national cancer institutenih as a research fellow in surgical oncology under steven a rosenberg md phd certified by the american board of urology and a fellow of the american college of surgeons dr belldegrun is licensed to practice in california new york virginia massachusetts and israel in addition to running an extremely busy urologic oncology surgery practice dr belldegrun is involved in many national and international cancer and biotechnology related committees serves on several advisory panels with such organizations as the national institutes for health and department of defense and serves on several editorial boards he is also on several scientific boards of biotechnology and pharmaceutical companies and serves as a reviewer for many medical journals and granting organizations in addition to holding several patents dr belldegrun is the author of several books on prostate and kidney cancers and has written over  scientific publications with an emphasis on urologic oncology particularly kidney prostate and bladder cancers dr belldegrun is married to dr rebecka belldegrun president of intertech corp and has four children two river  wikipedia two river from wikipedia the free encyclopedia jump to navigation search two river type limited liability company industry private equity venture capital founded  founder joshua kazam david tanen headquarters new york city new york key people arie belldegrun chairman products venture capital equity investment investment management website wwwtworivercom two river group holdings is a new yorkbased venture capital firm and merchant bank focused on the life science sector it specializes in investments in life science biotechnology and in firms focused on developing preventative and therapeutic technologies for a broad spectrum of disease areas including oncology cardiovascular disease neurological disorders and companion animal health care two river was founded in september  by partners joshua kazam peter kash david tanen and benjamin bernstein dr arie belldegrun joined the firm in  as chairman and partner the firm has offices in new york city and los angeles contents  portfolio  recent business  references  external links portfolioedit two river has invested in the following life science companies arno therapeutics otcbb arni  arno is a clinicalstage biopharmaceutical company that is developing innovative products for the treatment of cancer capricor therapeutics formerly nile therapeutics otcbb capr  capricor therapeutics inc is a publicly traded heart failure biotechnology company is focused on the development of novel therapeutics to prevent and treat heart disease cell design labs  cell design labs is a private biotherapeutics company pioneering breakthrough science to develop disruptive cellbased therapies for cancer and other devastating diseases cell design labs leverages the power of the body’s immune system to develop smart living therapies with the capability to treat our most challenging diseases with unprecedented power precision safety and durability edgemont pharmaceuticals  edgemont is a privately held pharmaceutical company with a primary focus and expertise in the field of neuroscience edgemont is committed to the development of novel drug formulations and new therapies that can improve patient care hubble  a brand of contact lenses sold directly to consumers through an ecommerce subscriptiononly model kite pharma nasdaq kite  kite pharma is a development stage biotechnology company engaged in the design and development of pioneering immune based targeted therapies to treat different cancer indications kite has a portfolio of proprietary product candidates designed to stimulate the patients own immune system to fight tumor cells sienna sienna biopharmaceuticals  sienna biopharmaceuticals is focused on the discovery clinical development and commercialization of products in dermatology and aesthetics based on scientific breakthroughs that dramatically improve patient outcomes and physicians’ practice of medicine urogen pharma  urogen pharma is a clinicalstage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for urological pathologies with a focus on urooncology velcera acquired by perrigo  velcera develops pet medicines in pain management antiallergy and parasiticides that can provide superior convenience and greater compliance than traditional products veterinary prime  developing premium pet nutrition products for dogs and cats sold exclusively through veterinarians recent businessedit in may  kite pharma completed a  million financing of series a preferred stock in october  arno therapeutics completed a  million financing of equity in november  nile therapeutics completed a merger with capricor to form capricor therapeutics capricor has become a wholly owned subsidiary of nile in february  velcera was acquired by perrigo for  million in april  kite pharma completed a  million mezzanine private financing of convertible notes and in may the company filed a registration with the sec for an ipo of its common stock with a proposed maximum offering price of  million the company listed on the nasdaq global market under the symbol “kite” the company planned to raise  million by offering  million shares at a price range of  to  at the midpoint of the proposed range kite pharma would command a market value of  million on  june   million shares of kite pharma priced at  a share began trading on the nasdaq indicating a market valuation of  million for the company in march  it was reported that two river has participated in a  million series a round of funding for hubble referencesedit  two river group holdings llc board committees businessweek retrieved  december   company overview of two river group holdings llc businessweek retrieved on  june   joshua a kazam businessweek retrieved on  june   david m tanen businessweek retrieved on  june   benjamin bernstein businessweek retrieved on  june   dr arie s belldegrun md facs joins two river group holdings as chairman and partner reuters  april  retrieved  june   portfolio two river retrieved on  august   elliott peter  may  kite pharma completes  million series a preferred stock financing istreetwire retrieved  june   arno therapeutics completes  million financing recapitalization and for reverse stock split  the wall street journal new york  october  retrieved  october   capricor and nile therapeutics complete merger to form capricor therapeutics inc  bloomberg  november  retrieved  december   ail pallavi  february  perrigo expands further into pet care with velcera deal reuters retrieved  april   kite pharma inc completes  million mezzanine private financing marketwatch  april  retrieved  april   kite pharma kite files m ipo streetinsider  may  retrieved  may   kite pharma files registration statement for proposed initial public offering digital journal  may  retrieved  may   dion don  june  ipo for kite pharma might fly high seeking alpha retrieved  june    us ipos planned for the week of jun  nasdaq  june  retrieved  june   calia michael  june  kite pharma soars above ipo price on first day of trading the wall street journal retrieved  june   kite pharma kite ipo surges higher streetinsider  june  retrieved  june   kolodny lora  march  hubble raises  million to deliver affordable daily contact lenses techcrunch retrieved  march  external linksedit two river  official website two river on businessweek retrieved from httpsenwikipediaorgwindexphptitletworiveroldid categories companies established in investment banking private equity groupsprivate equity firms of the united statescompanies based in new yorkventure capital firms of the united statesinvestment companies based in new york city navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view two river  wikipedia two river from wikipedia the free encyclopedia jump to navigation search two river type limited liability company industry private equity venture capital founded  founder joshua kazam david tanen headquarters new york city new york key people arie belldegrun chairman products venture capital equity investment investment management website wwwtworivercom two river group holdings is a new yorkbased venture capital firm and merchant bank focused on the life science sector it specializes in investments in life science biotechnology and in firms focused on developing preventative and therapeutic technologies for a broad spectrum of disease areas including oncology cardiovascular disease neurological disorders and companion animal health care two river was founded in september  by partners joshua kazam peter kash david tanen and benjamin bernstein dr arie belldegrun joined the firm in  as chairman and partner the firm has offices in new york city and los angeles contents  portfolio  recent business  references  external links portfolioedit two river has invested in the following life science companies arno therapeutics otcbb arni  arno is a clinicalstage biopharmaceutical company that is developing innovative products for the treatment of cancer capricor therapeutics formerly nile therapeutics otcbb capr  capricor therapeutics inc is a publicly traded heart failure biotechnology company is focused on the development of novel therapeutics to prevent and treat heart disease cell design labs  cell design labs is a private biotherapeutics company pioneering breakthrough science to develop disruptive cellbased therapies for cancer and other devastating diseases cell design labs leverages the power of the body’s immune system to develop smart living therapies with the capability to treat our most challenging diseases with unprecedented power precision safety and durability edgemont pharmaceuticals  edgemont is a privately held pharmaceutical company with a primary focus and expertise in the field of neuroscience edgemont is committed to the development of novel drug formulations and new therapies that can improve patient care hubble  a brand of contact lenses sold directly to consumers through an ecommerce subscriptiononly model kite pharma nasdaq kite  kite pharma is a development stage biotechnology company engaged in the design and development of pioneering immune based targeted therapies to treat different cancer indications kite has a portfolio of proprietary product candidates designed to stimulate the patients own immune system to fight tumor cells sienna sienna biopharmaceuticals  sienna biopharmaceuticals is focused on the discovery clinical development and commercialization of products in dermatology and aesthetics based on scientific breakthroughs that dramatically improve patient outcomes and physicians’ practice of medicine urogen pharma  urogen pharma is a clinicalstage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for urological pathologies with a focus on urooncology velcera acquired by perrigo  velcera develops pet medicines in pain management antiallergy and parasiticides that can provide superior convenience and greater compliance than traditional products veterinary prime  developing premium pet nutrition products for dogs and cats sold exclusively through veterinarians recent businessedit in may  kite pharma completed a  million financing of series a preferred stock in october  arno therapeutics completed a  million financing of equity in november  nile therapeutics completed a merger with capricor to form capricor therapeutics capricor has become a wholly owned subsidiary of nile in february  velcera was acquired by perrigo for  million in april  kite pharma completed a  million mezzanine private financing of convertible notes and in may the company filed a registration with the sec for an ipo of its common stock with a proposed maximum offering price of  million the company listed on the nasdaq global market under the symbol “kite” the company planned to raise  million by offering  million shares at a price range of  to  at the midpoint of the proposed range kite pharma would command a market value of  million on  june   million shares of kite pharma priced at  a share began trading on the nasdaq indicating a market valuation of  million for the company in march  it was reported that two river has participated in a  million series a round of funding for hubble referencesedit  two river group holdings llc board committees businessweek retrieved  december   company overview of two river group holdings llc businessweek retrieved on  june   joshua a kazam businessweek retrieved on  june   david m tanen businessweek retrieved on  june   benjamin bernstein businessweek retrieved on  june   dr arie s belldegrun md facs joins two river group holdings as chairman and partner reuters  april  retrieved  june   portfolio two river retrieved on  august   elliott peter  may  kite pharma completes  million series a preferred stock financing istreetwire retrieved  june   arno therapeutics completes  million financing recapitalization and for reverse stock split  the wall street journal new york  october  retrieved  october   capricor and nile therapeutics complete merger to form capricor therapeutics inc  bloomberg  november  retrieved  december   ail pallavi  february  perrigo expands further into pet care with velcera deal reuters retrieved  april   kite pharma inc completes  million mezzanine private financing marketwatch  april  retrieved  april   kite pharma kite files m ipo streetinsider  may  retrieved  may   kite pharma files registration statement for proposed initial public offering digital journal  may  retrieved  may   dion don  june  ipo for kite pharma might fly high seeking alpha retrieved  june    us ipos planned for the week of jun  nasdaq  june  retrieved  june   calia michael  june  kite pharma soars above ipo price on first day of trading the wall street journal retrieved  june   kite pharma kite ipo surges higher streetinsider  june  retrieved  june   kolodny lora  march  hubble raises  million to deliver affordable daily contact lenses techcrunch retrieved  march  external linksedit two river  official website two river on businessweek retrieved from httpsenwikipediaorgwindexphptitletworiveroldid categories companies established in investment banking private equity groupsprivate equity firms of the united statescompanies based in new yorkventure capital firms of the united statesinvestment companies based in new york city navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view two river  wikipedia two river from wikipedia the free encyclopedia jump to navigation search two river type limited liability company industry private equity venture capital founded  founder joshua kazam david tanen headquarters new york city new york key people arie belldegrun chairman products venture capital equity investment investment management website wwwtworivercom two river group holdings is a new yorkbased venture capital firm and merchant bank focused on the life science sector it specializes in investments in life science biotechnology and in firms focused on developing preventative and therapeutic technologies for a broad spectrum of disease areas including oncology cardiovascular disease neurological disorders and companion animal health care two river was founded in september  by partners joshua kazam peter kash david tanen and benjamin bernstein dr arie belldegrun joined the firm in  as chairman and partner the firm has offices in new york city and los angeles contents  portfolio  recent business  references  external links portfolioedit two river has invested in the following life science companies arno therapeutics otcbb arni  arno is a clinicalstage biopharmaceutical company that is developing innovative products for the treatment of cancer capricor therapeutics formerly nile therapeutics otcbb capr  capricor therapeutics inc is a publicly traded heart failure biotechnology company is focused on the development of novel therapeutics to prevent and treat heart disease cell design labs  cell design labs is a private biotherapeutics company pioneering breakthrough science to develop disruptive cellbased therapies for cancer and other devastating diseases cell design labs leverages the power of the body’s immune system to develop smart living therapies with the capability to treat our most challenging diseases with unprecedented power precision safety and durability edgemont pharmaceuticals  edgemont is a privately held pharmaceutical company with a primary focus and expertise in the field of neuroscience edgemont is committed to the development of novel drug formulations and new therapies that can improve patient care hubble  a brand of contact lenses sold directly to consumers through an ecommerce subscriptiononly model kite pharma nasdaq kite  kite pharma is a development stage biotechnology company engaged in the design and development of pioneering immune based targeted therapies to treat different cancer indications kite has a portfolio of proprietary product candidates designed to stimulate the patients own immune system to fight tumor cells sienna sienna biopharmaceuticals  sienna biopharmaceuticals is focused on the discovery clinical development and commercialization of products in dermatology and aesthetics based on scientific breakthroughs that dramatically improve patient outcomes and physicians’ practice of medicine urogen pharma  urogen pharma is a clinicalstage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for urological pathologies with a focus on urooncology velcera acquired by perrigo  velcera develops pet medicines in pain management antiallergy and parasiticides that can provide superior convenience and greater compliance than traditional products veterinary prime  developing premium pet nutrition products for dogs and cats sold exclusively through veterinarians recent businessedit in may  kite pharma completed a  million financing of series a preferred stock in october  arno therapeutics completed a  million financing of equity in november  nile therapeutics completed a merger with capricor to form capricor therapeutics capricor has become a wholly owned subsidiary of nile in february  velcera was acquired by perrigo for  million in april  kite pharma completed a  million mezzanine private financing of convertible notes and in may the company filed a registration with the sec for an ipo of its common stock with a proposed maximum offering price of  million the company listed on the nasdaq global market under the symbol “kite” the company planned to raise  million by offering  million shares at a price range of  to  at the midpoint of the proposed range kite pharma would command a market value of  million on  june   million shares of kite pharma priced at  a share began trading on the nasdaq indicating a market valuation of  million for the company in march  it was reported that two river has participated in a  million series a round of funding for hubble referencesedit  two river group holdings llc board committees businessweek retrieved  december   company overview of two river group holdings llc businessweek retrieved on  june   joshua a kazam businessweek retrieved on  june   david m tanen businessweek retrieved on  june   benjamin bernstein businessweek retrieved on  june   dr arie s belldegrun md facs joins two river group holdings as chairman and partner reuters  april  retrieved  june   portfolio two river retrieved on  august   elliott peter  may  kite pharma completes  million series a preferred stock financing istreetwire retrieved  june   arno therapeutics completes  million financing recapitalization and for reverse stock split  the wall street journal new york  october  retrieved  october   capricor and nile therapeutics complete merger to form capricor therapeutics inc  bloomberg  november  retrieved  december   ail pallavi  february  perrigo expands further into pet care with velcera deal reuters retrieved  april   kite pharma inc completes  million mezzanine private financing marketwatch  april  retrieved  april   kite pharma kite files m ipo streetinsider  may  retrieved  may   kite pharma files registration statement for proposed initial public offering digital journal  may  retrieved  may   dion don  june  ipo for kite pharma might fly high seeking alpha retrieved  june    us ipos planned for the week of jun  nasdaq  june  retrieved  june   calia michael  june  kite pharma soars above ipo price on first day of trading the wall street journal retrieved  june   kite pharma kite ipo surges higher streetinsider  june  retrieved  june   kolodny lora  march  hubble raises  million to deliver affordable daily contact lenses techcrunch retrieved  march  external linksedit two river  official website two river on businessweek retrieved from httpsenwikipediaorgwindexphptitletworiveroldid categories companies established in investment banking private equity groupsprivate equity firms of the united statescompanies based in new yorkventure capital firms of the united statesinvestment companies based in new york city navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view arie belldegrun md facs – kite pharma menu toggle navigation investorsmedia careers contact us home about us our mission management team board of directors scientific advisory board research our research technology pipeline clinical trials expanded access collaborations our collaborations joint ventures strategic collaborations car tcr enabling technologies kite world careers investor relations investor relations press releases events  presentations corporate governance — management team — board of directors — committee composition — contact the board financials  filings — sec filings — annual reports  proxies — quarterly results — key ratios stock information — historic stock lookup — investment calculator — dividend history — analyst coverage investor faqs contact us kite world arie belldegrun md facs management team  kite pharma menu toggle navigation investorsmedia careers contact us home about us our mission management team board of directors scientific advisory board research our research technology pipeline clinical trials expanded access collaborations our collaborations joint ventures strategic collaborations car tcr enabling technologies kite world careers investor relations investor relations press releases events  presentations corporate governance — management team — board of directors — committee composition — contact the board financials  filings — sec filings — annual reports  proxies — quarterly results — key ratios stock information — historic stock lookup — investment calculator — dividend history — analyst coverage investor faqs contact us management team arie belldegrun md facs chairman president  chief executive officer dr belldegrun has been a leader in developing novel cancer treatments and closely involved with the founding and advancement of several successful private and public biopharmaceutical companies in  he founded agensys inc a biotechnology company and served as its founding chairman and as a board member until  when it was acquired by astellas pharma inc from  to  he was the founding vicechairman of the board of directors and chairman of the scientific advisory board of cougar biotechnology inc until it was acquired by johnson  johnson dr belldegrun is the chairman of arno therapeutics inc two river group and urogen pharma ltd formerly theracoat ltd and currently serves as a board member of cell design labs he is also a member of the parker institute for cancer immunotherapy’s strategic advisory group in addition at the university of california los angeles ucla dr belldegrun is professor of urology holds the roy and carol doumani chair in urologic oncology and is director of the ucla institute of urologic oncology at the david geffen school of medicine prior to joining ucla he was a research fellow in surgical oncology and immunotherapy at the national cancer institutenih working under dr steven a rosenberg dr belldegrun earned his md at the hebrew university hadassah medical school in jerusalem he undertook his postgraduate studies in immunology at the weizmann institute of science and his residency in urologic surgery at the brigham and women’s hospital and harvard medical school in boston ma he has authored several books in oncology and more than  scientific and medical papers related to urological cancers immunotherapy gene therapy and cancer vaccines he is certified by the american board of urology and is a fellow of the american college of surgeons and the american association of genitourinary surgeons cynthia m butitta chief operating officer ms butitta has over  years of senior executive experience in the biotechnology and hightechnology industries she was most recently senior vice president and chief financial officer of nextwave pharmaceuticals inc which was acquired by pfizer in  prior to nextwave ms butitta served as chief operating officer from  to  and chief financial officer from  to  of telik inc a public biotechnology company focused on the development of small molecule drugs for the treatment of cancer while at telik ms butitta was responsible for securing over  million through an ipo and subsequent followon offerings from  to  ms butitta served as vice president of finance and administration and chief financial officer for connetics inc a public biotechnology company ms butitta received a bs degree with honors in business and accounting from edgewood college in madison wisconsin and a mba in finance from the university of wisconsin madison david d chang md phd executive vice president research  development and chief medical officer dr chang has an industryleading track record of innovation in the field of oncology drug development from  to  he held senior leadership roles at amgen including vice president of global development and head of hematologyoncology during this time dr chang spearheaded personalized therapy strategies that underlied the success of vectibix® panitumumab he also provided therapeutic area leadership to pivotal programs for blincyto® blinatumomab a bispecific t cell engager antibody in acute lymphocytic leukemia and for imlygic™ talimogene laherparepvec a firstofitskind oncolytic immunotherapy in melanoma prior to joining amgen dr chang held dual appointments as associate professor of medicine and of microbiology immunology and molecular genetics at the david geffen school of medicine at the university of california los angeles he obtained a bs degree in biology from the massachusetts institute of technology and md and phd degrees from stanford university dr chang completed an internship and residency in internal medicine at brigham and women’s hospital and a fellowship in medical oncology at danafarber cancer institute at harvard medical school where he was a howard hughes medical institute postdoctoral fellow christine cassiano senior vice president corporate communications and investor relations with a dual background in investor and public relations ms cassiano has an extensive history developing innovative approaches that advance communications in corporate positioning issues management employee engagement commercialization and investor relations ms cassiano was previously head of healthcare for the wo group an integrated healthcare marketing and communications consulting firm she previously cofounded arc communications  media a boutique agency that developed groundbreaking platforms for some of the largest companies in healthcare her more than year career includes multiple product launches across various therapeutic areas such as botox®botox® cosmetic onabotulinumtoxina prolia® denosumab abraxane® paclitaxel and lumigan® bimatoprost ophthalmic solution as well as leading global efforts as senior vice president  codirector healthcare at hill  knowlton strategies ms cassiano has held senior communications roles at biotechnology and pharmaceutical companies such as amgen allergan and abraxis bioscience some of ms cassiano’s career achievements include a sabre silver anvil award for the launch of botoxâ cosmetic allergan an in sabre award for the most innovative brandagency collaboration pfizerarc and pr week’s  under  paul jenkinson chief financial officer mr jenkinson brings nearly three decades of global financial experience in specialty pharmaceuticals and consumer product industries from  to  mr jenkinson worked at allergan inc from  to  at allergan mr jenkinson was vice president global commercial and corporate finance in this role he was responsible for the corporation’s financial planning and analysis activities and led the global commercial finance function with a focus on performance and systemwide revenue and cost management initiatives mr jenkinson worked closely with commercial operations manufacturing operations research and development and general and administration functions in multiple international markets while at allergan from  to  mr jenkinson held finance positions of increasing responsibility at the black  decker corporation presently stanley black  decker attaining the position of vice president corporate officer at the kwikset baldwin and weiser lock companies where he oversaw commercial finance and financial planning and analysis functions mr jenkinson qualified as an accountant while working at deloitte earlier in his career and he continues to be an active member of chartered accountants australia and new zealand he holds a bachelor of commerce degree in accounting  finance and marketing from the university of otago new zealand helen s kim executive vice president business development for more than  years ms kim has held leadership roles in biotechnology she served as strategic advisor of ngm biopharmaceuticals inc from january  to november  and as their chief business officer at ngm biopharmaceuticals inc from  to  prior to ngm she was the ceo and president of kosan biosciences inc where she restructured and repositioned the company prior to its acquisition by bristolmyers squibb in  additionally ms kim’s experience includes executive positions at affymax onyx pharmaceuticals protein design labs and chiron corporation where she served as head of global business development and marketing for therapeutics and vaccines businesses ms kim also recently served as chief program officer for the gordon and betty moore foundation she currently serves as a board member of sunesis pharmaceuticals forsight vision  and exicure therapeutics ms kim received a bs in chemical engineering from northwestern university and a mba from the university of chicago tim moore executive vice president technical operations tim moore has more than three decades of leadership experience in biopharmaceutical manufacturing and operations most recently he served as senior vice president head of global technical operations – biologics of genentech inc and as a member of the genentech executive committee since  in this role mr moore oversaw global leadership for more than  professionals across  internal sites and over  contract manufacturing organizations as well as global manufacturing and endtoend quality supply performance of more than  biological product families prior to that mr moore was genentech’s senior vice president global supply chain and global engineering from  to  previously mr moore served as vice president operations at zlb behring formerly aventis behring he is currently a member of ispe pda and has been a part of the executive committee of biophorum and the manufacturing leadership council mr moore received a bs in chemical engineering from tulsa university and a ms in engineering management from northwestern university shawn tomasello chief commercial officer ms tomasello has over three decades of experience in biotech and pharma her leadership career has positively impacted four blockbuster products in oncology including rituxan® revlimid® pomalyst® and imbruvica® previously ms tomasello was chief commercial officer at pharmacyclics until its acquisition by abbvie from  to  ms tomasello held roles of increasing responsibility at celgene corporation including president of the americas hematology and oncology where she managed more than  billion in revenue during her tenure at celgene ms tomasello was responsible for all aspects of the commercial organization encompassing multiple brands spanning  indications in addition she was instrumental in strategic decisionmaking regarding global expansion and ma evaluations which led to the acquisition and integration of pharmion corporation gloucester pharmaceuticals inc and abraxis biosciences inc prior to joining celgene ms tomasello was the national director of hematology for rituxan® at genentech where she was responsible for more than  billion in revenue and all inline and new indications for the hematology commercial sales organization earlier in her career she held positions at pfizer laboratories miles pharmaceuticals and proctor  gamble ms tomasello currently serves on the board of directors for oxford biotherapeutics and diplomat while at celgene she served as a board member of bionj and has been a member of the advisory board for healthcare businesswomen’s association hba ms tomasello received her bs in marketing from the university of cincinnati and her mba from murray state university ky kite pharma announces the appointment of arie belldegrun md as president and chief executive kite pharma announces the appointment of arie belldegrun md as president and chief executive officer apr    et from kite pharma inc santa monica calif april   prnewswire  kite pharma inc kite a clinicalstage biopharmaceutical company focused on developing engineered autologous t cell therapy eact™ products for cancer today announced the appointment of arie belldegrun md facs as president and chief executive officer  dr belldegrun who is also a founder of kite will continue in his current role as chairman of the company dr belldegrun has had a distinguished year tenure in the life sciences industry having been closely involved with the founding and advancement of successful private and public biopharmaceutical companies commented david bonderman speaking on behalf of kites board of directors  we are very pleased that he will take on his new role at kite as the company continues its momentum and further advances its broadly enabling platform in cancer immunotherapy prior to founding kite dr belldegrun was the founding vicechairman of the board of directors and chairman of the scientific advisory board of cougar biotechnology acquired by johnson  johnson in  in a  million transaction  previously dr belldegrun founded agensys and served as chairman of the board of directors  he also currently serves as chairman of arno therapeutics inc and as a board member of teva pharmaceutical industries ltd sonacare medical and theracoat  in addition dr belldegrun is professor of urology holds the roy and carol doumani chair in urologic oncology and is director of the ucla institute of urologic oncology at the david geffen school of medicine at ucla dr belldegrun completed his md training at the hebrew university hadassah medical school in jerusalem his postdoctoral in immunology research at the weizmann institute of science israel and his residency in urologic surgery at the brigham and womens hospital harvard medical school  he also completed a research fellowship in surgical oncology and immunotherapy under steven a rosenberg md phd at the national cancer institutenih  dr belldegrun has authored several books in oncology and more than  scientific and medical papers related to urologic cancers immunotherapy gene therapy and cancer vaccines  he is certified by the american board of urology and is a fellow of the american college of surgeons and of the american association of genitourinary surgeons about kite pharmakite pharma inc kite is a privately held clinicalstage biopharmaceutical company engaged in the development of novel cancer immunotherapy products with a primary focus on eact™ designed to restore the immune systems ability to recognize and eradicate tumors  in partnership with the nci surgery branch through a cooperative research and development agreement crada kite is advancing a pipeline of proprietary eact™ product candidates both car chimeric antigen receptor and tcr t cell receptor products directed to a wide range of cancer indications  kites management team has a proven track record of building successful biotechnology companies and successfully developing cuttingedge immunotherapies and oncology treatments  kite is based in santa monica ca kite contactcynthia m butittachief financial officer and chief operating officer for media justin jacksonfor investor inquiries kimberly minarovichburns mcclellan jjacksonburnsmccomkminarovichburnsmccom     source kite pharma inc view table fullscreen view table fullscreen journalists and bloggers the news you need when you need it join pr newswire for journalists to access all of the free services designated to make your job easier in need of subject matter experts for your story submit a free profnet request and find the sources you need learn more apr    et preview kite pharma expands companys board of directors with the appointment of jonathan m peacock mar    et preview kite pharma announces fda orphan drug designation for anticd t cell cancer immunotherapy product my news release contains wide tables view fullscreen looking to send a news release with pr newswire take advantage of the worlds leading distribution platform sign up to get started request more information have an account log in search searching for your content advanced search  pharmaceutical industries ltd see tevas sites around the world americas canada curacao united states growth markets argentina australia belarus brazil chile china india israel kazakhstan mexico peru russia singapore south africa turkey ukraine uruguay uzbekistan japan  s korea japan south korea europe europe austria belgium bosnia  herzegovina bulgaria croatia czech republic denmark estonia finland france germany greece hungary ireland italy latvia lithuania macedonia monaco netherlands norway poland portugal romania serbia slovakia slovenia spain sweden switzerland united kingdom see all see less want to find out more about tevas locations and phone numbers visit teva worldwide home page   go to parent page not found   home page    site map    contact us share on facebookshare on linkedin  ✉ forbes welcomeclose more options quote of the day only those who dare to fail greatly can ever achieve greatly robert f kennedy politician arni arie s belldegrun insider trades for arno therapeutics inc bulletin investor alert expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close arno therapeutics inc otc arni go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus arno therapeutics inc market closed  quotes are delayed by  min jul    pm arni quoteszigmandelayed   change   volume volume  quotes are delayed by  min quoteszigmandelayed previous close     change   day low day high    week low  week high   insider activity individual arie s belldegrun dr arie s belldegrun md is executive chairman at kite pharma inc chairman at arno therapeutics inc chairman  partner at two river group holdings llc chairman at two river group management llc chairman at two rivers consulting corp director at a nile therapeutics inc professor at california state universitylos angeles and chairman at theracoat ltd he has been closely involved with the founding development and sale of several private and public biopharmaceutical companies in  he founded agensys inc and served as its founding chairman of the board of directors he was also the founding vicechairman of the board of directors and chairman of the scientific advisory board of cougar biotechnology inc that was acquired by johnson  johnson in  dr belldegrun completed his md at the hebrew university hadassah medical school in jerusalem his post graduate fellowship at the weizmann institute of science and his residency in urological surgery at harvard medical school he is professor of urology holds the roy and carol doumani chair in urologic oncology and director of the ucla institute of urologic oncology at the david geffen school of medicine at ucla he is certified by the american board of urology and is a fellow of the american college of surgeons and the american association of genitourinary surgeons dr belldegrun is the chairman of arno therapeutics inc two river group and urogen pharma ltd formerly theracoat ltd and currently serves as a board member of teva pharmaceutical industries ltd transactions date shares transaction value     acquisition at  per share      acquisition at  per share      award at  per share      derivativenonderivative trans at  per share      award at  per share      acquisition at  per share      derivativenonderivative trans at  per share      award at  per share      acquisition at  per share      derivativenonderivative trans at  per share      award at  per share      acquisition at  per share      derivativenonderivative trans at  per share                                                              copyright  factset research systems inc all rights reserved source factset fundamentals officers and executives dr alexander a zukiwski ceo principal financial officer  director trending tickers quoteszigmancomposite vuzi quoteszigmancomposite jcp quoteszigmancomposite nugt quoteszigmancomposite jnug quoteszigmancomposite tlt x powered by log in  am edt july   marketstatecountryus new york closed marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest ptrump says he has ‘complete power to pardon’ plawmakers reach deal on russia sanctions bill reports palphabet earnings a  billion hit for google potential youtube results for investors pyou can date someone who looks just like donald trump with this new online service pwant to buy happiness splurge on these  things pthis is what people really buy when they emotionally overspend hint it’s not designer clothes pjohn mccain is a war hero — but think twice before saying he’s ‘battling’ cancer pthe dark side of cruises pi want to buy my brothers out of our family home — but they want me to pay future sales fees poj simpson made over  while in prison and won’t have to give any of it to the goldman family pnot even free money can make some people go to the gym phow realestate tv shows determine what buyers look for in a house pwhat eleanor roosevelt and helen gurley brown ate — and what we can learn from it pnote to parents this social network was rated the worst for teenage cyberbullying pif like sean spicer you suddenly quit your job — what should you do next pthis is the deadliest time of your life to put on weight p unfortunate reasons why millennials can’t have nice things or save any money pus giving takeover bids by chinese firms much tougher look pjared kushner discloses dozens of additional assets in revised filing pbitcoin surges as miners avert split for now loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  arie belldegrun md  penn lsm facebook linked in penn lsm search the programabout the program community where our grads go program leadership roy vagelos advisory board admissionsgeneral information quaker day  preparing for lsm transfer student profiles curriculumdual degree lsmspecific courses wharton courses college courses sample schedules study abroad internships  researchlearning through experience seeking opportunities internship faqs past internships internship funds innovation  entrepreneurshipsynapse dr lectures benz prize vagelos prizes givegive arie belldegrun md professor of urologychief division of urologic oncologydirector institute of urologic oncology roy and carol doumani chair in urologic oncologyucla school of medicine   dr belldegrun is director of the institute of urologic oncology at ucla professor of urology and chief of the division of urologic oncology he holds the roy and carol doumani chair in urologic oncology at the david geffen school of medicine at the university of california los angeles ucla in  dr belldegrun founded agensys inc an earlystage privatelyheld biotechnology company based in los angeles california that is focused on the development of fully human monoclonal antibodies to treat solid tumor cancers in a variety of cancer targets dr belldegrun served as founding chairman of agensys from  to  and then as a director until december  when the company was acquired by astellas pharma dr belldegrun served as vice chairman of the board and chairman of the scientific advisory board of cougar biotechnology inc a los angelesbased biopharmaceutical company from december  until its acquisition by johnson  johnson in july  since march  dr belldegrun has served as a director of arno therapeutics inc a publiclyheld new jerseybased biopharmaceutical company focused on the treatment of cancer patients dr belldegrun has also served as executive chairman of the board of directors of kite pharma inc a privatelyheld californiabased biotechnology company dedicated to the development of pioneering immunebased cancer therapies since its inception in  from february  to december  dr belldegrun also served on the board of directors of hana biosciences inc a publiclyheld biopharmaceutical company he is also chairman and partner of two river group holdings llc a new york based venture capital firm dr belldegrun also serves as an officer of the managing member of two river consulting llc an organization that provides management consulting and operational services for development stage biotechnology companies including nile dr belldegrun s prior experience also includes serving as principal investigator of more than  clinical trials of anticancer drug candidates and therapies dr belldegrun completed his md at the hebrew university hadassah medical school in jerusalem his post graduate fellowship at the weizmann institute of science and his residency in urological oncology at harvard medical school prior to ucla dr belldegrun was at the national cancer institutenih as a research fellow in surgical oncology under steven a rosenberg md phd he is certified by the american board of urology and is a fellow of the american college of surgeons and the american association of genitourinary surgeons site map  email lsm  vagelos program in life sciences  management    s university ave levin  philadelphia pa    arie belldegrun  wikipedia arie belldegrun from wikipedia the free encyclopedia jump to navigation search arie s belldegrun born  age – israel residence los angeles california citizenship israeli and american alma mater hadassah medical center weizmann institute of science occupation chairman president and ceo of kite pharma years active present net worth us billion  spouses rebecka belldegrun children  relatives poju zabludowicz brotherinlaw arie s belldegrun born  is an israeliborn american urologic oncologist businessman and investor contents  early life and academia  career ventures  agensys  cougar biotechnology  two river  kite pharma  other board memberships  recent business  personal life  references  external links early life and academiaedit belldegrun was born in israel he received his medical degree from the hadassah medical center at hebrew university of jerusalem in  and conducted his postgraduate studies at the weizmann institute of science in  he completed his urologic surgery residency at harvard medical school in  and his surgical oncology fellowship at the national cancer institute in  he is certified by the american board of urology and is a fellow of the american college of surgeons and the american association of genitourinary surgeons belldegrun is the director of the ucla institute of urologic oncology professor of urology and chief of the division of urologic oncology at the david geffen school of medicine career venturesedit agensysedit in  belldegrun established agensys an earlystage privately held biotechnology company based in los angeles that is focused on the development of fully human monoclonal antibodies to treat solid tumor cancers in a variety of cancer targets he served as its founding chairman of the board of directors from  to  and then as a director until december  when agensys was acquired by astellas pharma in a deal valued at  million cougar biotechnologyedit belldegrun has been a founding vice chairman of the board of directors and chairman of the scientific advisory board of cougar biotechnology since  a los angelesbased company with a focus in the field of oncology in july  the company was acquired by johnson  johnson in a  million transaction in april  the united states food and drug administration approved abiraterone acetate zytiga cougar’s lead product for late stage prostate cancer two riveredit since  belldegrun has been the chairman and partner of two river a new yorkbased venture capital firm and merchant bank focused on the life science sector it specializes in investments in life science biotechnology and in firms focused on developing preventative and therapeutic technologies for a broad spectrum of disease areas including oncology cardiovascular disease neurological disorders and companion animal health care kite pharmaedit belldegrun is the chairman president and ceo of kite pharma nasdaq kite which he founded in  kite pharma is a clinicalstage biopharmaceutical company engaged in the development of novel cancer immunotherapy products with a primary focus on engineered autologous t cell therapy eact™ designed to restore the immune systems ability to recognize and eradicate tumors the company went public in june  belldegrun who owns  million shares of the company has a stake worth over  million today other board membershipsedit belldegrun also serves as a member of the following boards arno therapeutics otcbb arni  chairman since march  urogen pharma formerly theracoat  chairman since october  cell design labs  director oncura  chairman of the medical advisory board roei medical technologies  chairman of the medical advisory board pontifax  chairman lsm at the university of pennsylvania  member of the advisory board in the past belldegrun served as a member of a number of boards including teva nyse teva  director and vice chairman of the science  technology committee february  to january  sonacare medical formerly ushifu  director and urological advisor september  to  capricor therapeutics formerly nile therapeutics  director september  to november  talon therapeutics formerly hana biosciences  director chairman of the compensation committee and member of the nominating  governance committee april  to december  paramount acquisition  director june  to january  chem rx corporation  director june  to january  rencarex at wilex ag  chairman of the medical advisory board email real estatecom  director recent businessedit in may  theracoat a clinical stage specialty pharmaceutical company of which belldegrun is the chairman has raised  million in capital from private investors and venture funds also in may  kite pharma completed a  million financing of series a preferred stock in october  arno therapeutics completed a  million financing of equity in november  nile therapeutics completed a merger with capricor to form capricor therapeutics otcbb capr capricor has become a wholly owned subsidiary of nile in february  velcera a portfolio company of two river was acquired by perrigo for  million in june  kite pharma sold  shares in their ipo at  per share for net proceeds of  million the company listed on the nasdaq global market under the symbol “kite” in may  it was announced that theracoat is seeking to raise more than  million in the coming months as it prepares for an initial public offering in new york the company will seek a valuation of about  million in the ipo in january  arno therapeutics completed a  million financing of equity in august  arno therapeutics completed a  million private placement of its common stock in april  urogen pharma formerly theracoat filed with the us securities and exchange commission sec to raise up to  million in an ipo on nasdaq the companys value has not yet been disclosed the company plans to list on the nasdaq under the symbol urgn jefferies and cowen  company are the joint bookrunners on the deal personal lifeedit belldegrun is married to dr rebecka belldegrun and together they have four children they reside in bel air an affluent neighborhood in los angeles their oldest son ben belldegrun a hedge fund manager is married to kelly bergantz senior producer for syco in  according to the bloomberg pay index belldegrun was ranked the th highestpaid executive in the united states with a pay package valued at  million in  the hollywood reporters annual hollywoods top doctors list included belldegrun as one of the highestrated urologists in  in its annual ranking of the wealthiest people in israel forbes israel ranked arie and rebecka belldegrun th with a personal net worth of ₪ billion equal to us billion belldegrun has written over  scientific publications related to urologic oncology and has authored several books on prostate and kidney cancers he was one of the speakers at the milken institute global conference  delivered the keynote andrew c novick memorial lecture at the ninth international kidney cancer symposium and regularly presents at the annual jp morgan healthcare conference it was announced that belldegrun will present at the th annual jp morgan healthcare conference in january  arie and rebecka belldegrun have donated over  million to the university of pennsylvania school of arts and sciences and have donated a  million sculpture to lacma referencesedit  a b  העשירים בישראל  in hebrew forbes israel  september  retrieved  september   a b curriculum vitae infofaq july  retrieved on  june   dr arie s belldegrun md facs joins two river group holdings as chairman and partner reuters  april  retrieved  june   arie belldegrun md archived july   at the wayback machine ucla health retrieved on  june   arie belldegrun md david geffen school of medicine retrieved on  june   a b arie belldegrun md usrf retrieved on  june   advisory board penn lsm retrieved on  august   moster roxanne  champeau rachel  november  ucla scientists biotech firm to be acquired by pharmaceutical corp ucla newsroom retrieved  june   board of directors archived june   at the wayback machine nile therapeutics retrieved on  june   johnson  johnson completes acquisition of cougar biotechnology archived november   at the wayback machine cougar biotechnology  july  retrieved  june   board of directors arno therapeutics retrieved on  june   company overview of two river group holdings llc businessweek retrieved on  june   about kite pharma archived january   at the wayback machine kite pharma retrieved  january   morrell alex  december  who got rich this week ucla doctor with a cancerfighting pharma firm forbes retrieved  march   a b arie s belldegrun md facs bloomberg business  august  retrieved on  august   advisory board university of pennsylvania retrieved  june   teva’s arie belldegrun resigns the pharma letter  january  retrieved  february   theracoat has completed a capital raising of m led by pontifax and chaim hurvitzs chealth fund the wall street journal  may  retrieved  june   elliott peter  may  kite pharma completes  million series a preferred stock financing archived april   at the wayback machine istreetwire retrieved  june   arno therapeutics completes  million financing recapitalization and for reverse stock split  the wall street journal new york  october  retrieved  october   capricor and nile therapeutics complete merger to form capricor therapeutics inc  bloomberg  november  retrieved  december   ail pallavi  february  perrigo expands further into pet care with velcera deal reuters retrieved  april   “kite pharma announces pricing of initial public offering” kite pharma  june  retrieved  august   calia michael  june  kite pharma soars above ipo price on first day of trading the wall street journal retrieved  june   “kite pharma announces full exercise of underwriters option to purchase additional shares” kite pharma  june  retrieved  august   wainer david  may  israel’s theracoat said to seek more than  million before ipo bloomberg retrieved  december   arno therapeutics completes  million common stock financing nasdaq  january  retrieved  january   arno completes  million private placement digital journal  august  retrieved  august   weinreb gali  tsipori tali  april  urogen pharma files for m nasdaq ipo globes retrieved  april   architecture project entries  aiany  retrieved on  june   kay richard  october  richard kay cowell girl gets the yes factor daily mail london retrieved  may   melin anders  chen caroline  june  biotech ceos among highestpaid us execs telegramcom retrieved  july   pyun jeanie  august   the hollywood reporter retrieved  november   nile therapeutics appoints arie s belldegrun md to board of directors reuters retrieved  november   us hifu appoints arie belldegrun md to board of directors reuters retrieved  november   global conference  archived november   at the wayback machine milken institute retrieved  november   medical symposia keynote addresses archived november   at the wayback machine kidney cancer association retrieved  november   kite pharma to present at the nd annual jp morgan healthcare conference bizjournals charlotte  january  retrieved  may   kite pharma to present at the th annual jp morgan healthcare conference nasdaq  january  retrieved  january   m lifetime donors to the school of arts and sciences university of pennsylvania  june  retrieved  june   smoke  lacma collections lacma retrieved  june   tony smiths monumental sculpture smoke will not disappear from lacma multimilliondollar purchase finalized los angeles times  june  retrieved  june  external linksedit arie belldegrun on bloomberg retrieved from httpsenwikipediaorgwindexphptitleariebelldegrunoldid categories  birthsliving peopleamerican bankersamerican chairmen of corporationsamerican health care businesspeopleamerican investorsamerican medical academicsamerican oncologistsamerican technology chief executivesamerican technology company foundersamerican urologistsamerican venture capitalistsbusinesspeople from los angelesbusinesspeople in the pharmaceutical industryhebrew university of jerusalem alumniisraeli emigrants to the united statesisraeli jewsjewish american bankersjewish physicianspeople from bel air los angelesphysicians from californiaweizmann institute of science alumnihidden categories webarchive template wayback linksarticles with hcards navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  june  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view creative commons — attributionsharealike  unported — cc bysa  skip to content menu help us build a vibrant collaborative global commons donate now creative commons creative commons license deed attributionsharealike  unported cc bysa  this is a humanreadable summary of and not a substitute for the license disclaimer you are free to share — copy and redistribute the material in any medium or format adapt — remix transform and build upon the material for any purpose even commercially the licensor cannot revoke these freedoms as long as you follow the license terms under the following terms attribution — you must give appropriate credit provide a link to the license and indicate if changes were made you may do so in any reasonable manner but not in any way that suggests the licensor endorses you or your use attribute this work sharealike — if you remix transform or build upon the material you must distribute your contributions under the same license as the original no additional restrictions — you may not apply legal terms or technological measures that legally restrict others from doing anything the license permits notices you do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation no warranties are given the license may not give you all of the permissions necessary for your intended use for example other rights such as publicity privacy or moral rights may limit how you use the material learn more about cc licensing or use the license for your own material this content is freely available under simple legal terms because of creative commons a nonprofit that survives on donations if you love this content and love that its free for everyone please consider a donation to support our work make a donation this page is available in the following languages castellano castellano españa català dansk deutsch english esperanto français galego hrvatski indonesia italiano latviski lietuvių melayu nederlands norsk polski português português br română slovenščina suomeksi svenska türkçe íslenska česky ελληνικά беларуская русский українська العربية پارسی     한국어 this content is freely available under simple legal terms because of creative commons a nonprofit that survives on donations if you love this content and love that its free for everyone please consider a donation to support our work when you share everyone wins contribute today to creative commons     disclaimer this deed highlights only some of the key features and terms of the actual license it is not a license and has no legal value you should carefully review all of the terms and conditions of the actual license before using the licensed material creative commons is not a law firm and does not provide legal services distributing displaying or linking to this deed or the license that it summarizes does not create a lawyerclient or any other relationship what does attribute this work mean the page you came from contained embedded licensing metadata including how the creator wishes to be attributed for reuse you can use the html here to cite the work doing so will also include metadata on your page so that others can find the original work as well the applicable mediation rules will be designated in the copyright notice published with the work or if none then in the request for mediation unless otherwise designated in a copyright notice attached to the work the uncitral arbitration rules apply to any arbitration more info if supplied you must provide the name of the creator and attribution parties a copyright notice a license notice a disclaimer notice and a link to the material cc licenses prior to version  also require you to provide the title of the material if supplied and may have other slight differences more info in  you must indicate if you modified the material and retain an indication of previous modifications in  and earlier license versions the indication of changes is only required if you create a derivative marking guide more info you may also use a license listed as compatible at httpscreativecommonsorgcompatiblelicenses more info a commercial use is one primarily intended for commercial advantage or monetary compensation more info merely changing the format never creates a derivative more info the license prohibits application of effective technological measures defined with reference to article  of the wipo copyright treaty more info the rights of users under exceptions and limitations such as fair use and fair dealing are not affected by the cc licenses more info you may need to get additional permissions before using the material as you intend more info arie belldegrun  wikipedia arie belldegrun from wikipedia the free encyclopedia jump to navigation search arie s belldegrun born  age – israel residence los angeles california citizenship israeli and american alma mater hadassah medical center weizmann institute of science occupation chairman president and ceo of kite pharma years active present net worth us billion  spouses rebecka belldegrun children  relatives poju zabludowicz brotherinlaw arie s belldegrun born  is an israeliborn american urologic oncologist businessman and investor contents  early life and academia  career ventures  agensys  cougar biotechnology  two river  kite pharma  other board memberships  recent business  personal life  references  external links early life and academiaedit belldegrun was born in israel he received his medical degree from the hadassah medical center at hebrew university of jerusalem in  and conducted his postgraduate studies at the weizmann institute of science in  he completed his urologic surgery residency at harvard medical school in  and his surgical oncology fellowship at the national cancer institute in  he is certified by the american board of urology and is a fellow of the american college of surgeons and the american association of genitourinary surgeons belldegrun is the director of the ucla institute of urologic oncology professor of urology and chief of the division of urologic oncology at the david geffen school of medicine career venturesedit agensysedit in  belldegrun established agensys an earlystage privately held biotechnology company based in los angeles that is focused on the development of fully human monoclonal antibodies to treat solid tumor cancers in a variety of cancer targets he served as its founding chairman of the board of directors from  to  and then as a director until december  when agensys was acquired by astellas pharma in a deal valued at  million cougar biotechnologyedit belldegrun has been a founding vice chairman of the board of directors and chairman of the scientific advisory board of cougar biotechnology since  a los angelesbased company with a focus in the field of oncology in july  the company was acquired by johnson  johnson in a  million transaction in april  the united states food and drug administration approved abiraterone acetate zytiga cougar’s lead product for late stage prostate cancer two riveredit since  belldegrun has been the chairman and partner of two river a new yorkbased venture capital firm and merchant bank focused on the life science sector it specializes in investments in life science biotechnology and in firms focused on developing preventative and therapeutic technologies for a broad spectrum of disease areas including oncology cardiovascular disease neurological disorders and companion animal health care kite pharmaedit belldegrun is the chairman president and ceo of kite pharma nasdaq kite which he founded in  kite pharma is a clinicalstage biopharmaceutical company engaged in the development of novel cancer immunotherapy products with a primary focus on engineered autologous t cell therapy eact™ designed to restore the immune systems ability to recognize and eradicate tumors the company went public in june  belldegrun who owns  million shares of the company has a stake worth over  million today other board membershipsedit belldegrun also serves as a member of the following boards arno therapeutics otcbb arni  chairman since march  urogen pharma formerly theracoat  chairman since october  cell design labs  director oncura  chairman of the medical advisory board roei medical technologies  chairman of the medical advisory board pontifax  chairman lsm at the university of pennsylvania  member of the advisory board in the past belldegrun served as a member of a number of boards including teva nyse teva  director and vice chairman of the science  technology committee february  to january  sonacare medical formerly ushifu  director and urological advisor september  to  capricor therapeutics formerly nile therapeutics  director september  to november  talon therapeutics formerly hana biosciences  director chairman of the compensation committee and member of the nominating  governance committee april  to december  paramount acquisition  director june  to january  chem rx corporation  director june  to january  rencarex at wilex ag  chairman of the medical advisory board email real estatecom  director recent businessedit in may  theracoat a clinical stage specialty pharmaceutical company of which belldegrun is the chairman has raised  million in capital from private investors and venture funds also in may  kite pharma completed a  million financing of series a preferred stock in october  arno therapeutics completed a  million financing of equity in november  nile therapeutics completed a merger with capricor to form capricor therapeutics otcbb capr capricor has become a wholly owned subsidiary of nile in february  velcera a portfolio company of two river was acquired by perrigo for  million in june  kite pharma sold  shares in their ipo at  per share for net proceeds of  million the company listed on the nasdaq global market under the symbol “kite” in may  it was announced that theracoat is seeking to raise more than  million in the coming months as it prepares for an initial public offering in new york the company will seek a valuation of about  million in the ipo in january  arno therapeutics completed a  million financing of equity in august  arno therapeutics completed a  million private placement of its common stock in april  urogen pharma formerly theracoat filed with the us securities and exchange commission sec to raise up to  million in an ipo on nasdaq the companys value has not yet been disclosed the company plans to list on the nasdaq under the symbol urgn jefferies and cowen  company are the joint bookrunners on the deal personal lifeedit belldegrun is married to dr rebecka belldegrun and together they have four children they reside in bel air an affluent neighborhood in los angeles their oldest son ben belldegrun a hedge fund manager is married to kelly bergantz senior producer for syco in  according to the bloomberg pay index belldegrun was ranked the th highestpaid executive in the united states with a pay package valued at  million in  the hollywood reporters annual hollywoods top doctors list included belldegrun as one of the highestrated urologists in  in its annual ranking of the wealthiest people in israel forbes israel ranked arie and rebecka belldegrun th with a personal net worth of ₪ billion equal to us billion belldegrun has written over  scientific publications related to urologic oncology and has authored several books on prostate and kidney cancers he was one of the speakers at the milken institute global conference  delivered the keynote andrew c novick memorial lecture at the ninth international kidney cancer symposium and regularly presents at the annual jp morgan healthcare conference it was announced that belldegrun will present at the th annual jp morgan healthcare conference in january  arie and rebecka belldegrun have donated over  million to the university of pennsylvania school of arts and sciences and have donated a  million sculpture to lacma referencesedit  a b  העשירים בישראל  in hebrew forbes israel  september  retrieved  september   a b curriculum vitae infofaq july  retrieved on  june   dr arie s belldegrun md facs joins two river group holdings as chairman and partner reuters  april  retrieved  june   arie belldegrun md archived july   at the wayback machine ucla health retrieved on  june   arie belldegrun md david geffen school of medicine retrieved on  june   a b arie belldegrun md usrf retrieved on  june   advisory board penn lsm retrieved on  august   moster roxanne  champeau rachel  november  ucla scientists biotech firm to be acquired by pharmaceutical corp ucla newsroom retrieved  june   board of directors archived june   at the wayback machine nile therapeutics retrieved on  june   johnson  johnson completes acquisition of cougar biotechnology archived november   at the wayback machine cougar biotechnology  july  retrieved  june   board of directors arno therapeutics retrieved on  june   company overview of two river group holdings llc businessweek retrieved on  june   about kite pharma archived january   at the wayback machine kite pharma retrieved  january   morrell alex  december  who got rich this week ucla doctor with a cancerfighting pharma firm forbes retrieved  march   a b arie s belldegrun md facs bloomberg business  august  retrieved on  august   advisory board university of pennsylvania retrieved  june   teva’s arie belldegrun resigns the pharma letter  january  retrieved  february   theracoat has completed a capital raising of m led by pontifax and chaim hurvitzs chealth fund the wall street journal  may  retrieved  june   elliott peter  may  kite pharma completes  million series a preferred stock financing archived april   at the wayback machine istreetwire retrieved  june   arno therapeutics completes  million financing recapitalization and for reverse stock split  the wall street journal new york  october  retrieved  october   capricor and nile therapeutics complete merger to form capricor therapeutics inc  bloomberg  november  retrieved  december   ail pallavi  february  perrigo expands further into pet care with velcera deal reuters retrieved  april   “kite pharma announces pricing of initial public offering” kite pharma  june  retrieved  august   calia michael  june  kite pharma soars above ipo price on first day of trading the wall street journal retrieved  june   “kite pharma announces full exercise of underwriters option to purchase additional shares” kite pharma  june  retrieved  august   wainer david  may  israel’s theracoat said to seek more than  million before ipo bloomberg retrieved  december   arno therapeutics completes  million common stock financing nasdaq  january  retrieved  january   arno completes  million private placement digital journal  august  retrieved  august   weinreb gali  tsipori tali  april  urogen pharma files for m nasdaq ipo globes retrieved  april   architecture project entries  aiany  retrieved on  june   kay richard  october  richard kay cowell girl gets the yes factor daily mail london retrieved  may   melin anders  chen caroline  june  biotech ceos among highestpaid us execs telegramcom retrieved  july   pyun jeanie  august   the hollywood reporter retrieved  november   nile therapeutics appoints arie s belldegrun md to board of directors reuters retrieved  november   us hifu appoints arie belldegrun md to board of directors reuters retrieved  november   global conference  archived november   at the wayback machine milken institute retrieved  november   medical symposia keynote addresses archived november   at the wayback machine kidney cancer association retrieved  november   kite pharma to present at the nd annual jp morgan healthcare conference bizjournals charlotte  january  retrieved  may   kite pharma to present at the th annual jp morgan healthcare conference nasdaq  january  retrieved  january   m lifetime donors to the school of arts and sciences university of pennsylvania  june  retrieved  june   smoke  lacma collections lacma retrieved  june   tony smiths monumental sculpture smoke will not disappear from lacma multimilliondollar purchase finalized los angeles times  june  retrieved  june  external linksedit arie belldegrun on bloomberg retrieved from httpsenwikipediaorgwindexphptitleariebelldegrunoldid categories  birthsliving peopleamerican bankersamerican chairmen of corporationsamerican health care businesspeopleamerican investorsamerican medical academicsamerican oncologistsamerican technology chief executivesamerican technology company foundersamerican urologistsamerican venture capitalistsbusinesspeople from los angelesbusinesspeople in the pharmaceutical industryhebrew university of jerusalem alumniisraeli emigrants to the united statesisraeli jewsjewish american bankersjewish physicianspeople from bel air los angelesphysicians from californiaweizmann institute of science alumnihidden categories webarchive template wayback linksarticles with hcards navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  june  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view arie belldegrun  wikipedia arie belldegrun from wikipedia the free encyclopedia jump to navigation search arie s belldegrun born  age – israel residence los angeles california citizenship israeli and american alma mater hadassah medical center weizmann institute of science occupation chairman president and ceo of kite pharma years active present net worth us billion  spouses rebecka belldegrun children  relatives poju zabludowicz brotherinlaw arie s belldegrun born  is an israeliborn american urologic oncologist businessman and investor contents  early life and academia  career ventures  agensys  cougar biotechnology  two river  kite pharma  other board memberships  recent business  personal life  references  external links early life and academiaedit belldegrun was born in israel he received his medical degree from the hadassah medical center at hebrew university of jerusalem in  and conducted his postgraduate studies at the weizmann institute of science in  he completed his urologic surgery residency at harvard medical school in  and his surgical oncology fellowship at the national cancer institute in  he is certified by the american board of urology and is a fellow of the american college of surgeons and the american association of genitourinary surgeons belldegrun is the director of the ucla institute of urologic oncology professor of urology and chief of the division of urologic oncology at the david geffen school of medicine career venturesedit agensysedit in  belldegrun established agensys an earlystage privately held biotechnology company based in los angeles that is focused on the development of fully human monoclonal antibodies to treat solid tumor cancers in a variety of cancer targets he served as its founding chairman of the board of directors from  to  and then as a director until december  when agensys was acquired by astellas pharma in a deal valued at  million cougar biotechnologyedit belldegrun has been a founding vice chairman of the board of directors and chairman of the scientific advisory board of cougar biotechnology since  a los angelesbased company with a focus in the field of oncology in july  the company was acquired by johnson  johnson in a  million transaction in april  the united states food and drug administration approved abiraterone acetate zytiga cougar’s lead product for late stage prostate cancer two riveredit since  belldegrun has been the chairman and partner of two river a new yorkbased venture capital firm and merchant bank focused on the life science sector it specializes in investments in life science biotechnology and in firms focused on developing preventative and therapeutic technologies for a broad spectrum of disease areas including oncology cardiovascular disease neurological disorders and companion animal health care kite pharmaedit belldegrun is the chairman president and ceo of kite pharma nasdaq kite which he founded in  kite pharma is a clinicalstage biopharmaceutical company engaged in the development of novel cancer immunotherapy products with a primary focus on engineered autologous t cell therapy eact™ designed to restore the immune systems ability to recognize and eradicate tumors the company went public in june  belldegrun who owns  million shares of the company has a stake worth over  million today other board membershipsedit belldegrun also serves as a member of the following boards arno therapeutics otcbb arni  chairman since march  urogen pharma formerly theracoat  chairman since october  cell design labs  director oncura  chairman of the medical advisory board roei medical technologies  chairman of the medical advisory board pontifax  chairman lsm at the university of pennsylvania  member of the advisory board in the past belldegrun served as a member of a number of boards including teva nyse teva  director and vice chairman of the science  technology committee february  to january  sonacare medical formerly ushifu  director and urological advisor september  to  capricor therapeutics formerly nile therapeutics  director september  to november  talon therapeutics formerly hana biosciences  director chairman of the compensation committee and member of the nominating  governance committee april  to december  paramount acquisition  director june  to january  chem rx corporation  director june  to january  rencarex at wilex ag  chairman of the medical advisory board email real estatecom  director recent businessedit in may  theracoat a clinical stage specialty pharmaceutical company of which belldegrun is the chairman has raised  million in capital from private investors and venture funds also in may  kite pharma completed a  million financing of series a preferred stock in october  arno therapeutics completed a  million financing of equity in november  nile therapeutics completed a merger with capricor to form capricor therapeutics otcbb capr capricor has become a wholly owned subsidiary of nile in february  velcera a portfolio company of two river was acquired by perrigo for  million in june  kite pharma sold  shares in their ipo at  per share for net proceeds of  million the company listed on the nasdaq global market under the symbol “kite” in may  it was announced that theracoat is seeking to raise more than  million in the coming months as it prepares for an initial public offering in new york the company will seek a valuation of about  million in the ipo in january  arno therapeutics completed a  million financing of equity in august  arno therapeutics completed a  million private placement of its common stock in april  urogen pharma formerly theracoat filed with the us securities and exchange commission sec to raise up to  million in an ipo on nasdaq the companys value has not yet been disclosed the company plans to list on the nasdaq under the symbol urgn jefferies and cowen  company are the joint bookrunners on the deal personal lifeedit belldegrun is married to dr rebecka belldegrun and together they have four children they reside in bel air an affluent neighborhood in los angeles their oldest son ben belldegrun a hedge fund manager is married to kelly bergantz senior producer for syco in  according to the bloomberg pay index belldegrun was ranked the th highestpaid executive in the united states with a pay package valued at  million in  the hollywood reporters annual hollywoods top doctors list included belldegrun as one of the highestrated urologists in  in its annual ranking of the wealthiest people in israel forbes israel ranked arie and rebecka belldegrun th with a personal net worth of ₪ billion equal to us billion belldegrun has written over  scientific publications related to urologic oncology and has authored several books on prostate and kidney cancers he was one of the speakers at the milken institute global conference  delivered the keynote andrew c novick memorial lecture at the ninth international kidney cancer symposium and regularly presents at the annual jp morgan healthcare conference it was announced that belldegrun will present at the th annual jp morgan healthcare conference in january  arie and rebecka belldegrun have donated over  million to the university of pennsylvania school of arts and sciences and have donated a  million sculpture to lacma referencesedit  a b  העשירים בישראל  in hebrew forbes israel  september  retrieved  september   a b curriculum vitae infofaq july  retrieved on  june   dr arie s belldegrun md facs joins two river group holdings as chairman and partner reuters  april  retrieved  june   arie belldegrun md archived july   at the wayback machine ucla health retrieved on  june   arie belldegrun md david geffen school of medicine retrieved on  june   a b arie belldegrun md usrf retrieved on  june   advisory board penn lsm retrieved on  august   moster roxanne  champeau rachel  november  ucla scientists biotech firm to be acquired by pharmaceutical corp ucla newsroom retrieved  june   board of directors archived june   at the wayback machine nile therapeutics retrieved on  june   johnson  johnson completes acquisition of cougar biotechnology archived november   at the wayback machine cougar biotechnology  july  retrieved  june   board of directors arno therapeutics retrieved on  june   company overview of two river group holdings llc businessweek retrieved on  june   about kite pharma archived january   at the wayback machine kite pharma retrieved  january   morrell alex  december  who got rich this week ucla doctor with a cancerfighting pharma firm forbes retrieved  march   a b arie s belldegrun md facs bloomberg business  august  retrieved on  august   advisory board university of pennsylvania retrieved  june   teva’s arie belldegrun resigns the pharma letter  january  retrieved  february   theracoat has completed a capital raising of m led by pontifax and chaim hurvitzs chealth fund the wall street journal  may  retrieved  june   elliott peter  may  kite pharma completes  million series a preferred stock financing archived april   at the wayback machine istreetwire retrieved  june   arno therapeutics completes  million financing recapitalization and for reverse stock split  the wall street journal new york  october  retrieved  october   capricor and nile therapeutics complete merger to form capricor therapeutics inc  bloomberg  november  retrieved  december   ail pallavi  february  perrigo expands further into pet care with velcera deal reuters retrieved  april   “kite pharma announces pricing of initial public offering” kite pharma  june  retrieved  august   calia michael  june  kite pharma soars above ipo price on first day of trading the wall street journal retrieved  june   “kite pharma announces full exercise of underwriters option to purchase additional shares” kite pharma  june  retrieved  august   wainer david  may  israel’s theracoat said to seek more than  million before ipo bloomberg retrieved  december   arno therapeutics completes  million common stock financing nasdaq  january  retrieved  january   arno completes  million private placement digital journal  august  retrieved  august   weinreb gali  tsipori tali  april  urogen pharma files for m nasdaq ipo globes retrieved  april   architecture project entries  aiany  retrieved on  june   kay richard  october  richard kay cowell girl gets the yes factor daily mail london retrieved  may   melin anders  chen caroline  june  biotech ceos among highestpaid us execs telegramcom retrieved  july   pyun jeanie  august   the hollywood reporter retrieved  november   nile therapeutics appoints arie s belldegrun md to board of directors reuters retrieved  november   us hifu appoints arie belldegrun md to board of directors reuters retrieved  november   global conference  archived november   at the wayback machine milken institute retrieved  november   medical symposia keynote addresses archived november   at the wayback machine kidney cancer association retrieved  november   kite pharma to present at the nd annual jp morgan healthcare conference bizjournals charlotte  january  retrieved  may   kite pharma to present at the th annual jp morgan healthcare conference nasdaq  january  retrieved  january   m lifetime donors to the school of arts and sciences university of pennsylvania  june  retrieved  june   smoke  lacma collections lacma retrieved  june   tony smiths monumental sculpture smoke will not disappear from lacma multimilliondollar purchase finalized los angeles times  june  retrieved  june  external linksedit arie belldegrun on bloomberg retrieved from httpsenwikipediaorgwindexphptitleariebelldegrunoldid categories  birthsliving peopleamerican bankersamerican chairmen of corporationsamerican health care businesspeopleamerican investorsamerican medical academicsamerican oncologistsamerican technology chief executivesamerican technology company foundersamerican urologistsamerican venture capitalistsbusinesspeople from los angelesbusinesspeople in the pharmaceutical industryhebrew university of jerusalem alumniisraeli emigrants to the united statesisraeli jewsjewish american bankersjewish physicianspeople from bel air los angelesphysicians from californiaweizmann institute of science alumnihidden categories webarchive template wayback linksarticles with hcards navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  june  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view data dumps    freebase api deprecated    google developers freebase api deprecated all products sign in send feedback hey there are you maybe looking for firebase instead data dumps the freebase api will be completely shutdown on aug   this page provides access to the last available data dump read more data dumps are a downloadable version of the data in freebase they constitute a snapshot of the data stored in freebase and the schema that structures it and are provided under the same ccby license the freebasewikidata mappings are provided under the cc license freebase triples freebase deleted triples freebasewikidata mappings license citing freebase triples this dataset contains every fact currently in freebase total triples  billion updated weekly data format ntriples rdf license ccby  gb gzip gb uncompressed download the rdf data is serialized using the ntriples format encoded as utf text and compressed with gzip rdf httprdffreebasecomnsgvjzynm httprdffreebasecomnsmeasurementunitdatedpercentagedate httpwwwworgxmlschemagyearmonth  httprdffreebasecomnsgvjzynm httprdffreebasecomnsmeasurementunitdatedpercentagesource httprdffreebasecomnsgxgfm  httprdffreebasecomnsgvjzynm httprdffreebasecomnstypeobjecttype httprdffreebasecomnsmeasurementunitdatedpercentage  httprdffreebasecomnsgvjzynm httprdffreebasecomnsmeasurementunitdatedpercentagerate   httprdffreebasecomnsgvjzynm httpwwwworgrdfsyntaxnstype httprdffreebasecomnsmeasurementunitdatedpercentage  if youre writing your own code to parse the rdf dumps its often more efficient to read directly from gzip file rather than extracting the data first and then processing the uncompressed data subject predicate object  note in freebase objects have mids that look like mrkqx in rdf those mids become mrkqx likewise freebase schema like commontopic are written as commontopic the subject is the id of a freebase object it can be a freebase mid ex mrkqx for topics and cvts or a humanreadable id ex commontopic for schema the predicate is always a humanreadable id for a freebase property or a property from a standard rdf vocabulary like rdfs freebase foreign key namespaces are also used as predicates to make it easier to look up keys by namespace the object field may contain a freebase mid for an object or a humanreadable id for schema from freebase or other rdf vocabularies it may also include literal values like strings booleans and numeric values topic descriptions often contain newlines in order to make each triple fit on one line we have escaped newlines with n freebase deleted triples we also provide a dump of triples that have been deleted from freebase over time this is a onetime dump through march  in the future we might consider providing periodic updates of recently deleted triples but at the moment we have no specific timeframe for doing so and are only providing this onetime dump the dump is distributed as a targz file gb compressed gb uncompressed it contains  deleted triples in  files there is no particular meaning to the individual files it is just easier to manipulate several smaller files than one huge file thanks to chun how tan and john giannandrea for making this data release possible total triples  million updated june   data format csv license ccby  gb gzip gb uncompressed download the data format is essentially csv with one important caveat the object field may contain any characters including commas as well as any other reasonable delimiters you could think of however all the other fields are guaranteed not to contain commas so the data can still be parsed unambiguously the columns in the dataset are defined as creationtimestamp unix epoch time in milliseconds creator deletiontimestamp unix epoch time in milliseconds deletor subject mid predicate mid object midliteral languagecode csv usermwclwikipediaenusermwclwikipediaenmrtypeobjectkeywikipediaenben usermwclmusicbrainzuserturtlewaxbotmnncpzmusicrecordingartistmvbfmen usermwclimagesusergardeningbotmwmcommonimagesizemklyen usermwclmusicbrainzusermbzpipelinemergebotmfvvltypeobjecttypecommontopicen usermwclimagesusergardeningbotmxsczcommonlicensedobjectlicensemxben usercontentadministratorusergardeningbotmgkbytypeobjecttypetypecontenten usermwclimagesusergardeningbotmhcommontopicimagemcsen usermwclchefmozuserdeletebotmzcztypeobjectnamela casa rosa mexican restauranten freebasewikidata mappings the data has been created based on the wikidatadump of october   and contains only those links that have at least two common wikipedialinks and not a single disagreeing wikipedialink furthermore the lines are sorted by the number of common wikipedialinks although in turtle this does not really matter total triples m updated october   data format ntriples rdf license cc  mb gzip mb uncompressed download the rdf data is serialized using the ntriples format encoded as utf text and compressed with gzip rdf httprdffreebasecomnsmj httpwwwworgowlsameas httpwwwwikidataorgentityq  httprdffreebasecomnsmnrg httpwwwworgowlsameas httpwwwwikidataorgentityq  httprdffreebasecomnsmjgd httpwwwworgowlsameas httpwwwwikidataorgentityq  httprdffreebasecomnsmd httpwwwworgowlsameas httpwwwwikidataorgentityq  httprdffreebasecomnsmgd httpwwwworgowlsameas httpwwwwikidataorgentityq  license freebase data dumps are provided free of charge for any purpose with regular updates by google they are distributed like freebase itself under the creative commons attribution aka ccby and use is subject to the terms of service the freebasewikidata id mappings are provided under cc and can be used without restrictions citing if youd like to cite these data dumps in a publication you may use google freebase data dumps httpsdevelopersgooglecomfreebasedata month day year or as bibtex bibtex misc except as otherwise noted the content of this page is licensed under the creative commons attribution  license and code samples are licensed under the apache  license for details see our site policies java is a registered trademark of oracle andor its affiliates last updated february   send feedback about this page documentation feedback freebase api deprecated product feedback cancel